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1. Summary 
 
The Ser/Thr kinase mammalian target of rapamycin (mTOR) regulates cell growth in 
response to extracellular stimulation with growth factors and to intracellular factors that sense 
the nutritional and the energy state of the cell. mTOR forms two distinct multiprotein 
complexes, the rapamycin-sensitive mTOR complex 1 (mTORC1) and mTORC2. Most 
characterized functions of mTOR are mediated by mTORC1. However, direct investigation of 
the in vivo function in most tissues including brain and muscle has been occluded by the 
early embryonic lethality of deficient mice for all mTORC1 members. Here, I describe the 
generation and characterization of mice that are deficient for raptor, an essential component 
of mTORC1, in skeletal muscle fibers and the developing brain. 
 
Analysis of the raptor-deficient brain reveals a general growth defect that evenly affects the 
whole organ. A decrease in cell size and cell number underlies the observed microcephaly. 
This is in accordance to earlier studies which assign to mTORC1 a role as controller of cell 
size and cell cycle. Beside this, mTORC1 controls several more specific aspects of brain 
development. Glial differentiation is disturbed and this is paralleled by a decrease of Stat3 
activity, a member of the Jak/Stat pathway that was previously involved in gliogenesis. Loss 
of the glial network in the dentate gyrus likely causes malformations of the developing 
granule cell layer. Furthermore, I describe an unexpected role of mTORC1 in the formation of 
hippocampal and cortical layers. 
 
Muscle-specific knockout (ko) mice develop a progressive muscle dystrophy and show 
changes in muscle metabolism. Based on alterations in the activation state and expression 
levels, we provide evidence that this phenotype is accounted for by PGC1α as well as 
Akt/PKB. 
 
In summary, this work provides evidence, that raptor is important for postnatal survival both, 
in muscle and the brain. Beside the generalized changes in cell growth, both ko models 
provide first evidence in vivo that mTORC1 regulates specific aspects of metabolism and that 
it differentially affects both glial and neuronal differentiation by affecting cell-specific 
pathways. 
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2. General introduction 
 
The macrolide rapamycin is produced by the bacterium Streptomyces hygroscopicus as an 
antifungal agent [1]. The bacterium was isolated from an Easter Island (indigenous name: 
Rapa Nui) soil sample and the antibiotic purified and characterized [2-4]. Later, the 
immunosuppressant activity of rapamycin was discovered [5] and manifested by identification 
of its ability to inhibit T-cell proliferation [6]. Like for the other immunosuppressant drugs 
cyclosporin A and FK-508, its primary receptor is the immunophilin FKBP [7]. In a genetic 
screen for targets of the complex of FKBP and rapamycin in the budding yeast 
Sachharomyces cerevisiae, two homologous proteins were identified and termed target of 
rapamycin 1 (TOR1) and TOR2 [8]. 
 
The TOR gene was subsequently identified in other eukaryotes, but occurred only in one 
copy [9]. The mammalian ortholog of TOR is called mTOR, which was previously also named 
FRAP, RAFT, RAP or SEP [10]. In parallel to the situation in yeast [11], mTOR forms two 
distinct multiprotein complexes [12, 13]. mTOR complex 1 (mTORC1) consists of mTOR, 
raptor (regulatory associated protein of mTOR), mLST8 and PRAS40 [14]. Beside mTOR, 
mTORC2 harbors rictor (rapamycin insensitive companion of mTOR), mSIN1 and mLST8. 
mTORC1 is sensitive to acute application of rapamycin, whereas long term treatment may 
interfere with the new formation of mTORC2 by titrating away free mTOR [15]. Analysis of 
the TOR pathway “from yeast to man” revealed a conserved role of TOR as nutrient sensor 
and as controller of cell growth [16]. 
 
 
2.1. The mTORC1 and mTORC2 pathway 
 
Due to the ease of rapamycin application and probably also because of the more prominent 
and more severe phenotypes that are associated with deletion of mTORC1, mTORC2 was 
much later described and its function is still less characterized. The two mTOR complexes, 
however, are probably differentially regulated and have different effectors [12, 13]. 
 
2.1.1. Upstream factors of mTOR 
 
mTORC1 reacts on extracellular and on intracellular signals that bear information about the 
nutritional state of the cell and the organism [16]. Best characterized is its function as sensor 
for growth factors, ATP levels and amino acid levels. 
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In numerous studies, mTOR was described to mediate insulin and IGF signaling via a 
signaling cascade consisting of the Insulin or IGF receptor, IRS, PI3K, PDK1, Akt/PKB, the 
TSC1/TSC2 complex and Rheb [10]. The TSC1/TSC2 complex and its direct downstream 
target Rheb thereby play a central role in linking the PI3K – Akt/PKB branch of the insulin 
signaling with mTOR [17]. In its GTP bound state, the small GTPase Rheb activates 
mTORC1, whereas nucleotide-free Rheb inhibits mTOR [18, 19]. The TSC complex, which is 
negatively regulated by Akt/PKB-mediated phosphorylation, acts as a GTPase activating 
protein (GAP) towards Rheb and thereby promotes GTP unloading from Rheb and 
inactivation of mTOR [17]. Unlike the growth factor pathway, amino acids do not signal 
through TSC [20] and do not change the Rheb-GTP levels [21]. Instead of class 1 PI3K like 
in the insulin signaling pathway, a role for the class 3 PI3K hVps34 was established in amino 
acid sensing and regulation of mTORC1, although the mechanism remains unclear [22, 23]. 
Recently, the Rag proteins, a family of four GTPases was identified to interact with mTOR 
and to be essential for amino acid induced mTORC1 activation [24]. The energy status of the 
cell is reflected by the activity level of AMPK. Low energy levels that go together with a high 
intracellular AMP/ATP level activate AMPK [25]. Activated AMPK can directly phosphorylate 
TSC in a way that enhances its GAP activity towards Rheb and inhibits mTORC1 [26]. 
 
Availability of insulin/IGF, amino acids and energy all regulate mTORC1 activity in a way that 
allows for an appropriate adjustment of cell growth. But these factors are by far not the only 
input on mTOR. In different cells and contexts, additional physiological signals can activate 
the mTOR pathway. For example, BDNF [27], Reelin [28], Leptin [29] and REDD-mediated 
oxidative stress [30] have been shown to modulate mTORC1 activity. 
 
Insulin and the PI3K pathway activate mTORC2. The TSC-complex promotes mTORC2 
kinase activity in a manner that is independent of its GAP-mediated Rheb activation [31]. 
TSC2 physically interacts with mTORC2 but the mechanism of activation is not currently 
understood [32]. 
 
2.1.2. Downstream effectors and general functions of mTOR 
 
The TOR pathway is a controller of eukaryotic cell growth. It collects input signal from various 
extracellular and intracellular sources and mediates a diverse set of cellular functions via 
several effectors [16]. Several principal mechanisms are known so far by which mTOR 
regulates appropriate cell growth. These include promotion of translation via enhanced 
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ribosome biogenesis and translation initiation, control of transcription and metabolism as well 
as the inhibition of autophagy. 
 
The best characterized direct mTORC1 downstream targets are S6K and 4E-BP1. They 
contribute at least to a substantial part to mTORC1 controlled translation. Via 
phosphorylation of 4E-BP1, mTOR regulates cap-dependent translation initiation. In the 
phosphorylated state, 4E-BP1 dissociates from eIF4E which in turn to associates with eIF4G 
and initiates translation [33]. Phosphorylated S6K also acts on the formation of the 
translation initiation complex. It phosphorylates eIF4B and ribosomal protein S6 [34]. eIF4B 
phosphorylation mediates its recruitment into the initiation complex and allows for the build 
up of the eIF4F translation initiation complex [35]. In contrast to previous belief, rapamycin-
sensitive translation of 5’-TOP RNA, a subgroup of mRNAs which encode ribosomal proteins 
and translation elongation factors, is not dependent on S6K [36]. For the interaction of 
mTORC1 with S6K and 4E-BP1, the protein raptor plays an important role. It mediates 
efficient binding specifically to a conserved 5 amino acid sequence in the N-terminal region 
of S6K and the C-terminal region of 4E-BP1, the so called TOR signaling (TOS) motif [37]. 
 
In addition to the short term activation of translation initiation, mTORC1 regulates also 
ribosome biogenesis which is required for long term growth [36]. mTOR promotes several 
steps of biosynthesis including production of rRNA by RNA Polimerase (Pol) I, ribosomal 
proteins by RNA Pol II and 5S rRNA by RNA Pol III [38]. S6K is necessary for Pol I activation 
and phosphorylation of the transcription factors UBF and Rrn3 are also involved in mTORC1 
mediated activation [39, 40]. But the exact mechanism by which all three RNA polymerases 
are controlled by mTOR remains unclear. 
 
mTOR also regulates transcription of many genes involved in metabolic and biosynthetic 
pathways [16]. Beside the regulation of ribosome biogenesis, mTORC1 also directly 
activates Stat1 and Stat3 [41]. By downregulation of the transcription factors PGC1α and 
PPARγ, mTORC1 is also involved in transcriptional control of mitochondrial and fat 
metabolism, respectively [42, 43]. TORC1 is an inhibitor of autophagy in several eukaryotes 
[44]. The role of mTOR in autophagy of mammals, its physiological importance and the 
mechanisms of regulation still need to be investigated. mTORC2 regulates phosphorylation 
of the kinases Akt/PKB [45], PKC [13] and SGK [46] at their hydrophobic motifs and 
modulates the actin cytoskeleton [12]. Loss of mTORC2 dependent Akt/PKB phosphorylation 
at Ser473 affects activity of only a subset of Akt targets, including FoxO1/3a [47], but not the 
mTORC1 upstream regulator TSC1/TSC2. 
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The downstream effects of mTOR are much more diverse than the ones depicted in the 
upper paragraph. Other mechanisms and physiological actions associated with mTOR 
signaling for example comprise cell cycle progression [48, 49], differentiation [50], local 
translation together with cell compartment restricted growth [51] and memory formation [52, 
53]. There is also an additional level of mTOR downstream effects which ignores the borders 
of the cell membrane. Whereas in single cell organisms, TOR regulates cell size and 
polarization [11], in multicellular organisms it controls cell and organ growth, but not 
exclusively via cell autonomous actions. For example, deletion of an amino acid transporter 
in the Drosophila larvae fat body causes inactivation of dTOR. Subsequently, this leads to a 
humoral response associated with a systemic growth inhibition of other tissues [54]. Under 
nutrient rich conditions, a factor is released from the fat body that stabilizes Drosophila 
insulin-like peptides (Dilp) and promotes insulin signaling and growth of peripheral tissues. 
When dTOR is not active, under nutrient poor conditions, this factor is no longer released 
and insulin signaling is inhibited. Another example of the way how mTOR influences whole 
organism size is its implication in regulation of appetite and food intake. Increased 
hypothalamic mTOR activity, due to high amino acid abundance or leptin signaling, 
decreases food intake and body weight [29]. 
 
 
2.2. Functions of mTOR in muscle 
 
Especially because of its dependence on growth factors and on mTORC1 upstream and 
downstream factors, mTOR signaling was found to be involved in the control of muscle 
growth [55]. In the adult muscle, growth is associated with gain of individual fiber size rather 
than increase of fiber number. A balance of protein synthesis and degradation is especially 
important for the regulation of muscle growth or wasting. 
 
Deregulation of muscle growth is associated with several pathologic states like muscle 
wasting of HIV patients, cachexia which accompanies devastating diseases, age-induced 
sarcopenia or simple disuse atrophy [56]. In many of them, the IGF signaling is involved [57]. 
 
Genetic mouse models revealed that ablation of the mTOR-upstream component Akt/PKB 
[58] and the downstream effector S6K [59] induce atrophy. In contrast, overexpression of 
Akt/PKB [60, 61] and IGF-1 [62] is sufficient to induce muscle hypertrophy. Mice that 
overexpress the negative regulator of mTOR, TSC1, in skeletal muscle show growth defects 
[63].Further evidence for an involvement of mTORC1 in these mechanisms comes from the 
observation, that Akt/PKB induced hypertrophy is rapamycin sensitive [64, 65]. Moreover, 
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branched chain amino acids, but in particular the strong mTORC1 activator leucine, help in 
the build-up of muscle by induction of protein synthesis [66]. 
 
In addition to the regulation of protein synthesis, activation of the IGF-1/PI3K/Akt/PKB 
pathway was found to prevent induction of the atrophy mediators MAFbx and MuRF1 via Akt-
mediated inhibition of FoxO1 [67] or via mTOR [68]. 
 
 
2.3. Functions of mTOR in the developing and adult brain 
 
During brain growth, mTOR is thought to exert many functions. In vitro experiments implicate 
mTOR in mechanisms that are supposed to be crucial for several stages of brain 
development. 
 
In cultured neural stem cells, mTORC1 was found to drive differentiation either into the 
neuronal or the glial lineage [50, 69, 70]. Many studies addressed mTORC1 functions in 
postmitotic neurons [71]. Neurons are highly organized cells. Axons and dendrites determine 
the structural and functional polarization. In addition to global cell growth, local mechanisms 
guide the formation of the cell compartments [72, 73]. mTORC1-dependent mechanisms 
were suggested to underlie specification and growth of axons [51, 74], growth and 
maintenance of dendrites [27, 75], growth cone guidance [76] and synaptogenesis [27, 77]. 
Mechanistically, regulation of local translation is believed to account for these effects [78, 
79]. Among the activity-and mTORC1-dependent newly synthesized proteins in synapto-
dendritic preparations, factors previously involved in dendrite growth or synaptogenesis were 
identified. 
 
In the adult brain, mTORC1 plays a role in synaptic plasticity and memory formation [71]. 
Expression of late-phase of LTP was found to be sensitive to rapamycin [80, 81]. This was 
the case even in dendrites that were severed from their somas, further supporting the 
concept of local translation in synaptic plasticity [82]. Localized rapamycin application into the 
auditory cortex of Mongolian gerbils prevents consolidation of long term memory [53]. In an 
additional study, rats that were subjected to post-training infusion of rapamycin performed 
worse in the Morris water maze paradigm, a typical test for hippocampus dependent long-
term memory formation [52]. 
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2.4. Aim of this study and contributions 
 
The goal of this study was to characterize the role of mTORC1 in brain development and in 
the muscle. Investigation of the function of mTORC1 in these tissues was previously 
prevented by the fact that null mutants of the individual mTORC1 components mTOR, raptor 
or mLST8 are embryonically lethal [83-85]. Therefore, a mouse model for the conditional 
deletion of raptor, an essential component of mTORC1, was generated. 
 
In order to specifically delete raptor in brain or muscle, we crossed our floxed mice to Nestin-
Cre and HSA (human skeletal actin)-Cre mice, respectively. Specificity of both Cre driver 
lines was previously described [86, 87]. Analysis of the raptor-deficient brain revealed 
several functions of mTORC1 during brain development. Phenotypes comprise global as well 
as specific aspects of brain development. In addition to the confirmation of the importance of 
mTORC1 in muscle growth, study of the raptor-deficient muscle phenotype revealed 
interesting new details of the role of mTORC1 in muscle physiology and metabolism. 
 
Analysis of the muscle was principally performed by Conrad Florian Bentzinger and Klaas 
Romanino. For examination of the function of mTOR in the muscle, rictor floxed mice were 
used which we had generated simultaneously to the raptor floxed mice. 
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3. Results 
3. 1. Paper 1 
 
 
Ablation of mTORC1 in the developing brain induces microcephaly, 
defects in glial differentiation and cortical layering 
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3.1.1. Summary 
 
The mammalian target of rapamycin (mTOR) regulates cell growth in response to various 
intracellular and extracellular signals. It assembles into two multiprotein complexes, the 
rapamycin-sensitive mTOR complex 1 (mTORC1) and the rapamycin-insensitive mTORC2. 
In this study, we deleted the gene of the functionally crucial mTORC1 component raptor in 
the developing mouse central nervous system. Such mice are viable for a few hours after 
birth. Analysis of the brain reveals that mTORC1-deficiency causes severe microcephaly due 
to both, a reduction of cell size and number. Experiments with cultured neurospheres show 
that the decreased cell number is due to decreased proliferation. Further, differentiation of 
neural stem cells into the glial lineage is inhibited in raptor-deficient mice. The 
underdeveloped radial glial network in the dentate gyrus thereby likely disturbs formation of 
the granule cell layer. Inhibition of gliogenesis is paralleled by a decreased protein and 
phosphorylation level of Stat3. In particular, this study establishes an unexpected role of 
mTORC1 in the migration of neurons in the cortex and hippocampus. Taken together, these 
results show that postnatal survival, overall brain growth and specific aspects of brain 
development critically depend on mTORC1 function. 
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3.1.2. Introduction 
 
In eukaryotes, cell growth is regulated by the TOR pathway. The mammalian ortholog mTOR 
contributes to two distinct multiprotein complexes refered to as mTORC1 and mTORC2 [12, 
13]. mTORC1 consists of mTOR, raptor, mLST8 and PRAS40 and is sensitive to acute 
treatment of the immunosuppressant rapamycin [16]. Like mTORC1, mTORC2 harbours 
mTOR and mLST8 but further contains rictor and mSIN1. Under prolonged rapamycin 
application, mTORC2 can be inhibited as well [15]. Whereas knowledge of the role of 
mTORC2 is sparse, mTORC1 has been implicated in the control of metabolism, protein 
translation, ribosome biogenesis, autophagy and transcription [16]. However, analysis of the 
physiological function of mTORC1 in vivo was for long time restricted to early embryonic 
development, due to the lethality of mTOR, raptor and mLST8-deficient embryos. mTOR-/- 
and raptor-/- embryos die shortly after implantation due to proliferation defects [83-85]. 
mLST8-/- mice phenocopy rictor-/- mice and reveal that mLST8 is not necessary for mTORC1-
dependent early embryonic development. Only later, at midgestation (E10.5), embryos die 
due to vascular defects in the fetal placenta and show additional embryonic defects.   
Brain development under conditions of reduced mTOR activity was addressed by a study 
which characterized a mutation in the mTOR gene that resulted in a splicing defect [88]. 
Mutant embryos lacked telencephali and died at midgestation. This effect was phenocopied 
by rapamycin application. Interpretation of these results is difficult since mTOR null embryos 
die much earlier in development [83, 85] and the prolonged rapamycin application does not 
allow to associate the contribution of either mTOR complex to the phenotype. Only recently, 
our lab developed mice with floxed raptor (regulatory associated protein of mTOR) alleles. 
These models allowed to overcome embryonic lethality and conferred specificity in the 
analysis of mTOR complexes 1. The floxed mice were used to conditionally ablate mTORC1 
in skeletal muscle or fat and these studies showed that mTORC1 exerts distinct functions in 
different tissues [89, 90]. 
Many valuable in vitro studies, however, have addressed mTOR function in different aspects 
of brain development. A few studies addressed differentiation of neural stem cells and came 
to the seemingly conflicting conclusions that mTORC1 is either crucial for commitment into 
the neuronal or into the glial lineage [50, 69, 70]. The highly defined context of these studies 
may explain such differences and poses the question to which extent the chosen conditions 
reflect the physiological situation. A large set of studies addressed consequences of mTOR 
inhibition or knockdown for growth of the postmitotic neurons [71]. Based on those studies, 
mTOR seems to be important for polarization, dendrite development and axonal growth or 
guidance. Complexity of the dendritic tree is reduced upon mTORC1 inhibition [27, 75]. For 
axons, some show that rapamycin-sensitive local translation in growth cones mediates axon 
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guidance or regrowth after axotomy [51, 91, 92]. Others show that axon specification and 
elongation is mTORC1 dependent [74]. In summary, in vitro data have resulted in a panoply 
of potential functions of mTORC1. However, its role in vivo has not been addressed. 
Prenatal brain development is a highly complex process. Cells proliferate extensively, 
differentiate and migrate and ultimately organize themselves into layers and nuclei. Many 
cells have to adopt highly branched structures. Axons have to be responsive to extracellular 
cues in order to form correct fiber lamination which depends on local translation [92]. For 
many of these steps of brain development, a role of the cell growth controller mTOR was 
established in vitro or was proposed. To define the physiological function of mTORC1 in 
brain development, we used a conditional mouse model to specifically delete raptor in the 
developing central nervous system (CNS). We find that raptor-deficient brains are smaller 
than control brains due to decreased cell size and reduced proliferation. Differentiation into 
the glial lineage and development of the layers is affected in the hippocampus and the cortex 
by removal of raptor. In summary, our results show that global brain growth as well as more 
specific aspects of brain development depends on mTORC1 function. 
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3.1.3. Results 
 
mTORC1 in the brain is not necessary for embryonic survival and body growth 
Mice that lack mTORC1 in the brain were generated by, crossing raptor-floxed mice [89] with 
mice that express Cre under control of the CNS stem cell-specific enhancer of the Nestin 
promoter [86, 93]. In the resulting raptorfl/fl;nestin-Cre mice (herein called RAbKO mice), Cre-
mediated recombination deletes exon 6 of the raptor gene and induces a frame shift, which 
causes a precocious stop of translation (Fig. 1A). Genotyping of E19.5 mouse embryos and 
newborn pups revealed approximately 25% of the offspring to be RAbKO mice, which 
reflects the Mendelian ratio. This shows that mTORC1 function in the developing CNS is not 
necessary for embryonic survival (Table 1).  
Recombination within the brain was confirmed by PCR (Fig. 1A,B). Genomic DNA of RAbKO 
mice showed a single band for the raptor floxed allele but no raptor wild-typ band and was 
positive for the Cre gene. Using primers P1 and P3, the band of the Cre-driven 
recombination was detected in brain but not in tail lysates. PCR with P1 and P2 primers 
revealed a decreased signal of the unrecombined raptor floxed allele in the brain compared 
to the tail. In contrast, double floxed control mice that were negative for the Cre gene showed 
no decrease of this band in the brain compared to the tail lysates. Equal amount of DNA was 
used for each PCR and the rictor wild-typ allele served as control. Western blot analysis of 
brain lysates also showed that the amount of raptor protein was strongly reduced in RAbKO 
(Fig. 1C). The residual raptor protein was probably present due to expression in meninges 
and blood vessels. mTOR and the mTORC2 member rictor were unchanged in RAbKO 
lysates. Loss of mTORC1 function was confirmed by Western blot against ribosomal protein 
S6, whose phosphorylation is mTORC1 dependent [36]. Whereas the level of the S6 protein 
was the same in control and RAbKO animals, phosphorylation at serine 235/236 was 
strongly reduced in RAbKO brains. 
RAbKO mice died within several hours after birth. In contrast to their control littermates, they 
never showed a milk belly. After a few hours, mice breathed improperly, got cyanotic and 
died (data not shown). Body weight of E19.5 RAbKO mice was normal indicating that 
mTORC1 in the brain has no role in prenatal body growth (Fig. 1D). 
 
raptor-deficient brains are smaller than control brains 
As mTORC1 is well known for its role in cell growth, we examined the brain size of E19.5 
mice. Analysis of the brains revealed that RAbKO brains are much smaller than control 
brains. Brain weight was reduced to 53.7% whereas the weight of heterozygous knockout 
brains was not changed, showing that one functional raptor allele is sufficient to maintain 
normal brain size during development (Fig. 2A). To investigate whether the reduction in size 
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was a global effect or attributed to distinct brain regions, brain sections of various levels 
along the rostro-caudal axis were stained with cresyl violet (Fig 2B). Comparison revealed 
that all major brain regions were smaller.  
The difference in size can be caused either by a decrease in cell size or cell number, 
mechanisms that are both in good accordance with the known functions of mTORC1 [16]. To 
discriminate between these two possibilities, we quantified the DNA content in brain lysates. 
The DNA amount is highly proportional to the number of cells and can be quantified by the 
enhancement of fluorescence of the fluorochrome Hoechst33258 to DNA [94]. This method 
was previously used to characterize the mechanisms of brain size changes in Akt3/PKBγ 
knockout mice [95, 96]. The DNA amount per brain was reduced in RAbKO animals to 
67.6%, indicating that they contain approximately 30 percent less cells (Fig. 2C). We further 
determined the amount of DNA per gram of brain tissue (Fig. 2D), which is a measure for cell 
density [96, 97]. DNA amount per gram of brain was increased to 124.4%, indicating that cell 
density is increased by the same ratio. Thus, cell size must be reciprocally decreased to 
about 80%. Neither cell number nor cell density was changed in the heterozygous RAbKO 
mice. As mTOR and mTORC1 deficiency or dysfunction causes proliferation defects in ES 
cells and early mouse embryonic development [83-85], we next asked whether the loss of 
cells in the RAbKO brain was caused by a reduced proliferation rate of neural stem- or 
progenitor cells. To address this question, we cultured P0 telencephalic neural stem cells of 
control and RAbKO mice as freely floating neurospheres. Raptor-deficient primary 
neurospheres grew much more slowly than spheres derived from control. To investigate the 
role of mTORC1 in neurosphere formation and growth, the same number of cells originating 
from control and RAbKO primary spheres were plated at clonal density and analyzed for their 
ability to generate secondary spheres. The number of secondary neurospheres was similar 
in RAbKO cultures (Fig. 2G), indicating that the number of self-renewing stem cells was 
unchanged [98]. The size of the neurospheres, however, was strongly reduced (Fig. 2E,F). 
The size distribution in RAbKO spheres is shifted towards smaller diameters compared to 
controls (Fig. 2F) and the Wilcoxon two sample test showed that the difference is highly 
significant (p < 1.384 x 10-12). This shows that the proliferative capacity of neural stem- or 
progenitor cells is decreased. Taken together, these data show that mTORC1 is necessary 
for proper brain growth which involves both, proliferation and cell growth. 
 
Glial differentiation is impaired in raptor deficient brains 
In vitro, mTORC1 has been suggested to regulate differentiation of neural stem cells and 
precursor cells towards the neuronal or glial lineage [50, 69, 70]. To investigate whether this 
would also apply in vivo, or whether the observed reduced proliferation rate would affect a 
particular precursor line, we analyzed the cellular composition of the RAbKO brain, using 
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Western blot analysis of E19.5 control and RAbKO brains (Fig. 3A). The signal of the neuron-
specific isoform β-tubulin III was not decreased in RAbKO brain lysates indicating that the 
proportion of neurons was unchanged. Similarly, brain lipid-binding protein (BLBP), a radial 
glial marker reflecting the number of neuronal precursors was not altered [99]. The same was 
the case for GAD65/67, a marker for the neuronal subpopulation of inhibitory interneurons 
with their distinct origin in the ganglionic eminence. These data indicate that mTORC1 is not 
essential for the differentiation of neural stem cells into the neuronal lineage. The astrocytic 
marker GFAP, however, was strongly reduced in RAbKO brain lysates, which led us to 
further investigate the glial lineage.  
To investigate the distribution of GFAP-positive cells in the brain, we made stainings of brain 
sections from newborns (Fig. 3B). At this time of development, GFAP-positive cells would 
only just start to populate the brain. Indeed, the signal was only apparent in a few regions. In 
the dentate gyrus of control brains, the GFAP-signal was quite prominent at the granule cell 
layer, whereas in RAbKO animals, the signal was much weaker. Distinct populations of early 
GFAP-positive cells are the three groups of cells that form the midline glial stuctures: the 
indusium griseum glia (IGG), the midline zipper glia (MZG) and the glial wedge (GW). They 
are thought to play a role in callosal axon guidance and some of them are GFAP-positive as 
early as E13 [100]. These populations were less pronounced in RAbKO mice when stained 
with an antibody against GFAP. This shows that glial cell populations in mTORC1-deficient 
brains are not efficiently generated or do not acquire an important glial characteristic, namely 
the expression of the intermediate filament protein GFAP.  
mTOR was previously linked to glial differentiation via its ability to phosphorylate Stat3 [50, 
101], which regulates astrocyte development [102, 103]. For maximal activation, 
phosphorylation of Stat3 at two residues, Tyr705 and Ser727 is required. Tyr705 is 
phosphorylated by members of the Jak/Tyk family, whereas Ser727 can be phosphorylated 
by mTORC1. Hence, we analyzed the expression and phosphorylation state of Stat3, in brain 
lysates of newborns (Fig. 3C). We found that the protein level as well as phosphorylation of 
both sites was decreased in RAbKO lysates, indicating that the overall activity of Stat3 is 
decreased. This result suggests that failure of mTORC1 mediated activation of Stat3 may 
underlie the depletion of GFAP-positive cells. 
To further analyze wether the lack of astrocytes represents a deficit of the raptor-deficient 
neural stem cells to differentiate into the glial lineage, we differentiated neurosphere cultures 
from RAbKO and control mice. Differentiation was achieved by culturing the dissociated 
spheres as attached cultures and removal of growth factors FGF2 and EGF. Staining with 
the anti-GFAP antibody revealed a lower fraction of GFAP-positive astrocytes after 5 days of 
differentiation (Fig. 3D). The fraction of neurons, however was not changed. This was further 
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confirmed by quantification (Fig. 3E) and Western blot probed for β-tubulin III and GFAP (Fig. 
3F). 
 
The pyramidal- and the granule cell layer do not form in the raptor deficient 
hippocampus 
One of the most obvious differences between E19.5 RAbKO and control mice apparent in 
Cresyl violet-stained brain sections was the lack of a proper pyramidal layer in the CA 
regions of the raptor-deficient hippocampus (Fig. 4A). Also, the dentate gyrus was not 
organized in a distinct C shaped layer and a hylus. We therefore examined the hippocampus 
closer at an earlier time point using several markers (Fig. 4A). Cresyl violet staining of E15.5 
brains revealed that in RAbKO mice, the hippocampal plate (HP) as well as the cortical plate 
(CP) were formed. At the same stage, Map2, a marker for dendrites and at early brain 
development also for the somata of subplate (SP) neurons [104, 105], formed a continuous 
band along the cortical subplate which ranges far into the control hippocampus. The Map2 
SP band in RAbKO brain was fading before it reached the hippocampus (filled arrow head, 
Fig. 4A). At E19.5, the Map2-positive SP band penetrated the hippocampus.  
Cresyl violet and Map2 staining both revealed a layering defect in the hippocampus of 
RAbKO mice. We therefore wanted to determine the localization of neurons in the 
hippocampus and stained with an antibody against the neuronal marker NeuN. At E15.5, no 
obvious difference in NeuN distribution was visible between genotypes. The NeuN signal 
was evenly distributed throughout the hippocampal CA- and dentate gyrus regions but was 
excluded from the ventricular zone (VZ). In contrast, at E19.5, distribution of postmitotic 
neurons was different in the RAbKO hippocampus. In the control hippocampus, neurons 
were densely packed at the ventricular surface of the pyramidal layer of the CA regions 
(open arrowhead). The dentate gyrus already showed the initial formation of the C shaped 
granule cell layer (arrow, Fig. 4A) and the hylus (asterisk Fig. 4A). In the RAbKO 
hippocampus however, neurons did not form a proper pyramidal layer (open arrowhead). In 
the dentate gyrus, which represents a secondary proliferation zone separated from the VZ, 
neurons were evenly filling the hylus and did not show the initial formation of the granule cell 
layer.  
We further addressed CA layering by application of BrdU. In control mice, most cells that had 
incorporated BrdU at E14.5 were integrated into the pyramidal cell layer at E19.5 (Fig. 4B). In 
the RAbKO hippocampus, BrdU-positive cells were found near and even within the VZ 
showing that mTORC1 is essential for the formation of a pyramidal layer in the CA regions 
and a defined granule cell layer in the dentate gyrus. 
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Cortical layer formation is affected by removal of raptor 
In contrast to the hippocampal organization, cortical layering of raptor-deficient brains was 
grossly normal when comparing Cresyl violet stained E19.5 brain sections (Fig. 5A). Map2-
stained brain sections revealed normal preplate splitting and SP formation in RAbKO brains 
(Fig 5B). When we further stained E19.5 brain sections for the neuronal marker NeuN, we 
found stongly positive neurons only in the SP and the upper CP for both genotypes (Fig. 5C). 
This is in agreement with a previous study where rapamycin application did not interfere with 
preplate splitting and early cortical plate formation [28].  
To further investigate whether and how cortical layering was affected, we injected BrdU into 
timed pregnant dams at different stages of embryonic development and analyzed the 
position of BrdU-positive cells at E19.5 or in newborns (Fig. 5D). When injected at E12.5, 
which is around preplate splitting, no obvious difference could be observed between control 
and RAbKO mice (data not shown). The BrdU signal was relatively concentrated at the SP 
and faded gradually towards the MZ. Only a few labeled cells were visible within the IZ. Cells 
that were generated at E14.5, however, showed a different pattern in the raptor-deficient 
cortex. Similar to the situation in the hippocampus (Fig. 4B), the signal was relatively 
concentrated in the VZ and IZ, below the SP, and relatively deprived from the CP (Fig. 5D,E). 
Within the control cortex however, they were localized more in the upper CP. When injected 
at E17.5, a time where the CP layer is almost complete [106], fewer BrdU-positive cells were 
localized in the CP of E19.5 RAbKO mice (data not shown). This indicates that neurons 
developing at E14.5 or later do migrate less efficiently into the CP. 
 
Raptor is necessary for normal formation of axonal tracts and dendritic complexity 
mTORC1 has previously been linked to axonal growth in several conditions [51, 74, 91]. 
According to these studies, initial specification as well as axonal elongation and steering are 
influenced by mTORC1 which would serve as regulator of local cell growth. We therefore 
examined the developing axonal tracts in E19.5 brains. Cresyl violet stainings of brain 
sections revealed that the size of several major axon tracts was reduced in raptor-deficient 
brains as shown for the corpus callosum (CC), the anterior commissure (AC) and the fimbria 
(Fig. 6A). Quantification of the CC thickness and the AC diameter showed strong and 
significant decreases in RAbKO brains (Fig. 6B). To exclude the possibility that reduced CC 
thickness was simply caused by a depletion of neurons in the cortex, we used Western blot 
analysis with the neuronal marker β-tubulin III (Fig. 6C). Several studies using rapamycin or 
RNAi against mTOR have shown that mTOR restricts dendrite development and 
maintenance [27, 75]. To quantify the reduction in a cell-autonomous system, we cultured 
hippocampal neurons from homozygously floxed E16.5 mice and transfected them at DIV4 
with an expression plasmid encoding Cre or a control plasmid. Both vectors were 
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cotransfected with a GFP-expressing plasmid to visualize the whole cell for the 
measurement. Sholl blot analysis at DIV 14 showed a significant decrease in the complexity 
of the dendritic tree (Fig. 6D). In conclusion, raptor-deficient neurons show growth defects 
including a simplification of the dendritic tree and an inability of the axons to form properly 
sized tracts in the brain. 
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3.1.4. Discussion 
 
In this study, we used Nestin-Cre mice together with the floxed raptor mice to delete raptor in 
the developing CNS. The resulting RAbKO mice showed a phenotype that affects cell size 
and proliferation in the entire brain which causes microcephaly. Beside this global effect, we 
also found several more specific aberrations affecting glia differentiation and radial migration 
of neurons in the cortex and hippocampus.  
 
Requirement of mTORC1 for normal brain growth 
RAbKO mice were born alive and were viable for several hours, indicating that the previously 
described embryonic death of the mTOR mutants or after rapamycin treatment during 
embryonic development was not mediated solely by mTORC1 ablation in the brain [88]. 
Analysis of the raptor deficient brain revealed that mTORC1 was not essential for 
telencephalon formation or initial formation of any other large brain structure. However, the 
size of the entire brain was smaller. The change in size was reminiscent of the brains of mice 
where Akt3/PKBγ, an mTORC1-upstream component, was knocked out [96]. However, the 
effect of the Akt3/PKBγ deletion is milder and these mice are viable. This might be due to the 
compensation of the other two Akt/PKB isoforms. Similar to the Akt3/PKBγ ko, we found that 
both cell size and number were decreased in raptor-deficient brains. Reduced cell size might 
be due to decreased activity of the well characterized mTORC1 effectors S6K/S6. A slower 
rate of proliferation was found to underlie the loss in cell number. Defects in proliferation are 
supposed to cause early embryonic death of mTOR and raptor null mice [84]. mTORC1 was 
previously associated with cell cycle control via G1 progression. A recent study defined a 
molecular mechanism whereby mTORC1 acts on the cell cycle by modulation of p27 activity 
via direct phosphorylation of SGK [49].  
The fact that the entire brain was homogenously smaller from early on suggested that 
already the earliest neural stem cells and all subsequent progenitors would be affected in a 
proportional way. However, the reduction in the number of glial cells was disproportional. 
This suggested that in addition to the regulation of proliferation, further mTORC1 dependent 
mechanisms regulate differentiation.  
 
mTORC1 is essential for the efficient gliogenesis and formation of the granule cell 
layer in the dentate gyrus 
The first GFAP-positive cells in the mouse brain appear at the corticoseptal boundary in the 
GW at E13 and are proposed to be part of the cortical radial glial network [100]. Later, they 
will become astrocytes. The other midline glial structures seem to have a different origin and 
to differentiate directly into astrocytes. Later in development, after the neurogenic to gliogenic 
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switch, radial glia cells also produce astrocytes in the cortex and hippocampus [107]. Among 
these are also the astrocyte stem cells that are responsible for adult neurogenesis in the 
subgranular zone of the dentate gyrus and the subventricular zone of the lateral ventricles. 
The fact that in RAbKO mice, both early and late generated GFAP populations are affected 
in a similar way shows that development is not simply delayed. Rather, glial differentiation is 
inhibited which was further proven by experiments with neural stem cell cultures from 
RAbKO mice or cultures from homozygously floxed mice that were transduced with a Cre-
expressing virus (Fig. 3D-F, Supplementory Figure 1). 
Whereas there is consensus that GFAP is not expressed in rodent radial glia [108], some 
work has shown that the radial glial scaffold in the dentate gyrus expresses GFAP during late 
embryonic development [109, 110]. Granule cell migration in the dentate gyrus is somewhat 
different from neuronal migration in the neocortex. Migration does not start directly in the 
ventricular zone but originates from the hylus of the dentate gyrus which represents a 
secondary proliferation zone. Therefore, it is not the classical radial glia scaffold which 
mediates migration and layer formation but a separate glial network in the hylus. Thus, a 
decrease in organization of the glial network of the dentate gyrus causes malformation of the 
granule cell layer [111]. In our mouse model, the malformation of the granule cell layer 
formation coincides with a generally decreased GFAP signal in the dentate gyrus. It was also 
obvious that cells were much more bound to the pial surface than in the control where many 
processes reached perpendicularly far into the hylar region (Fig. 3B). Elongation and 
organization of glia in the dentate gyrus depends on reelin. Parts of the effects of reelin were 
shown to be rapamycin sensitive, for example induction of dendrite growth [28]. It might 
therefore be that ablation of mTORC1 hits granule cell migration in two ways. First, it inhibits 
differentiation of the radial glial cells in the dentate gyrus. Subsequently, it might also 
influence growth of glial processes and formation of a proper migration scaffold. 
 
Reduction of GFAP positive cells correlates with decreased expression and mTORC1 
dependent activation of the Jak-Stat signaling member Stat3 
Activity of Stat3 is regulated both by phosphorylation at Tyr705 and Ser727 [101]. mTORC1 
was previously shown to be the kinase for Stat3 Ser727. Indeed, in brain lysates of RAbKO 
brains, we found phosphorylation of Stat3 at this site to be strongly reduced. Protein level of 
Stat3, however, was also decreased. This was probably caused by a failed induction of the 
positive autoregulatory feedback loop of activated Stat3 on transcription of genes of the Jak-
Stat pathway [112]. It was shown that the Stat pathway has to be activated first in order to 
allow for increased induction of transcription. This activation of the pathway came along with 
the switch of the neurogenic to the gliogenic period. It had been previously shown that the 
Jak-Stat pathway induces differentiation of astrocytes and can directly activate expression 
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from the GFAP promoter [102, 103]. This indicates that reduced GFAP in mTORC1-deficient 
brains is due to the inability of Stat3 to be phosphorylated and activated and thereby to 
initiate an enhanced Jak/Stat signaling that ultimately induces efficient gliogenesis. 
Interestingly, loss of the mTORC1 inhibitor TSC, a model for the genetic disease tuberous 
sclerosis in humans, induces Stat3 activation and GFAP expression [113]. By promotion of 
astrocyte differentiation or radial glial differentiation in the dentate gyrus, mTORC1 activated 
Stat3 should also mediate generation of neural stem cells responsible for adult 
neurogenesis. CNTF or Stat3 deletion, which inhibits generation of GFAP-positive cells, both 
cause reduced neurogenesis and reduce the size of the granule cell layer in the adult mouse 
[114]. Also deletion of Igf1, a classical upstream factor of mTOR results in loss of granule 
cells in the hippocampus [115]. This suggests that mTORC1 may play a pivotal role in adult 
neurogenesis. 
 
A novel role for mTORC1 in cortical cell migration 
In raptor-deficient brain, both the developing granule cell layer of the dentate gyrus and the 
pyramidal cell layer of the CA regions were perturbed. Whereas layering in the hippocampus 
was clearly deficient, malformations in the cortex were not obvious in cresyl violet stained 
RAbKO brain sections. BrdU birthdating experiments revealed that early born neurons 
migrate properly which is in agreement with a previous slice culture study where rapamycin 
had no effect on preplate splitting and early CP layering [28]. Interestingly, we found now that 
mTORC1 deficiency affected cortical and hippocampal architecture at a later stage. When 
BrdU was injected at E14.5, a fraction of labeled cells remained in the VZ/IZ of mTORC1 
depleted brains whereas in control brains, BrdU puncta were much more abundant in the CP. 
This suggests that in contrast to earlier generated cells, neurons born after E14.5 are 
partially trapped in the VZ/IZ. Before newly generated neurons penetrate the SP and migrate 
through the CP, they gather in the IZ and change their morphology from multipolar to bipolar 
[116]. Interference with this transition takes place in several mouse models with cortical 
migration defects due to inhibited CP penetration [117-119]. This is also the case for the 
cortex specific Cdk5 ko mouse, the hippocampus of which shows a similar phenotype like the 
one of RAbKO mice [120]. In addition, axonal trajectories of Cdk5 mutants were abnormal, a 
phenotype that also occurs in the raptor deficient brain. This suggests that a polarity defect 
which inhibits the transition of the multipolar to dipolar state might account for the observed 
migration defects in RAbKO brains. The fact that we find the dendritic complexity to be 
reduced in vitro together with studies that manifest the role of mTORC1 in dendritic growth or 
in axon specification further support this view. 
In conclusion, our data shows that mTORC1 is crucial for normal brain growth and postnatal 
survival. Several aspects of brain development are affected by mTORC1 ablation and may in 
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sum be responsible for death of the newborns. Regulation of cell size and division, which are 
both affected in RAbKO mice, are processes that are known to be associated with mTORC1 
signaling. mTORC1 induced phosphorylation of Stat3 allows for normal differentiation of 
GFAP positive glia and thereby probably promotes normal layering in the dentate gyrus. Our 
results further uncover a novel role for mTORC1 in cortical layering, the detailed mechanism 
of which is not entirely clear. The multiple phenotypes of this mouse reflect the central 
position of mTORC1 in processing signals of several pathways and forewarding the output to 
various downstream effectors. 
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3.1.5. Materials and methods 
 
Brain-specific raptor knockout mice 
Mice homozygous for the floxed raptor allele were mated with mice that were heterozygous 
for the floxed allele and further expressed Cre under the control of the CNS-specific 
enhancer of the Nestin promoter. Time matings were made and E15.5, E19.5 embryos or 
newborns were taken for analysis. Genotyping was performed on tail or brain lysates using 
primers depicted in Fig. 1A. P1: 5'-ATG GTA GCA GGC ACA CTC TTC ATG; P2: 5'-GCT 
AAA CAT TCA GTC CCT AAT C; P3: 5'-CAG ATT CAA GCA TGT CCT AAG C; Cre-forward: 
5'-TGT GGC TGA TGA TCC GAA TA; Cre-backward: 5'-GCT TGC ATG ATC TCC GGT AT. 
For comparative PCR, 2.5 μg template DNA was used for each PCR reaction. Mice that were 
heterozygous or homozygous for the floxed raptor allele and were negative for Cre were 
taken as control. 
 
Antibodies 
The following rabbit polyclonal antibodies were used: mTOR, S6 Ribosomal Protein, P-S6 
Ribosomal Protein (Ser235/236), P-Stat3 (Ser727) from Cell Signaling, BLBP, Map2 from 
Chemicon and GAD65/67 from Sigma. Rabbit monoclonal antibodies were as follows: raptor, 
rictor, P-Stat3 (Tyr705) and β-Actin from Cell Signaling. Mouse monoclonal antibodies were 
as follows: Stat3 from Cell Signaling, NeuN and GFAP from Chemicon, β-Tubulin III from 
Sigma. Rat monoclonal antibodies are were follows: BrdU from AbD Serotec. 
 
Brain lysates for Western blots 
Brains of embryos or newborns were dissected, washed in ice-cold PBS and combined with 
10x (volume/weight) lysis buffer (50 mM Tris at pH 8, 150 mM NaCl, 1mM EDTA, 1% Triton-
X100) supplemented with protease inhibitor cocktail tablets (Roche) and phosphatase 
inhibitor cocktail I and II (Sigma). Brains were passed several times through a 1 ml pipette tip 
and homogenized with a glass-teflon homogenizer by using 12 strokes at 800 rpm. Lysates 
were centrifuged at at 13600 rpm for 15 min at 4°C. Total protein levels were then 
determined using the BCA protein assay (Pierce) and supplied with sample buffer. Equal 
amounts of protein were loaded onto SDS gels, transferred to nitrocellulose membranes and 
probed for the indicated antibodies. 
 
Brain sections, histochemistry and immunohistochemistry 
For fresh frozen sections, dissected brains were embedded in OCT reagent and directly 
frozen on dry ice. 10 μm-thick brain sections were prepared with a cryostat, dried and frozen 
at -70°C or directly postfixed with 4% PFA in PBS for 20 min and washed in PBS for further 
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analysis. For paraffin sections, brains were fixed for at least two days in 4% PFA in PBS, 
then dehydrated in a graded alcohol series and embedded in paraffin. 4μm-thick sections 
were prepared on a microtome. For further applications, mounted sections were 
deparaffinized by heating for 20 min at 65°C, then immediately immersed twice in Xylol for 5 
min each. Sections were rehydrated and either directly subjected to cresyl violet staining and 
haematoxilin/eosin staining or antigen retrieval was performed. For this, slides were boiled in 
sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6) for 20 min and allowed 
to cool slowly for another 20 min at room temperature. Sections were washed with PBS for 
further analysis. For immunohistochemistry, sections were blocked for 30 min in PBS 
containing 5% BSA and 0.25% Triton-X100. Slices were incubated over-night at 4°C in 
blocking buffer with one of the following primary antibodies: GFAP (1:200), NeuN (1:200), 
Map2 (1:400), BrdU (1:2000). Subsequently, slides were washed 3 x with PBS for 5 min 
each and incubated with appropriate secondary antibodies and DAPI in blocking buffer for 1 
h at room temperature. After washing in PBS, coverslips were mounted with Kaiser’s glycerol 
gelatine. 
 
Birthdating analysis 
For birthdating analysis in the cortex, 50 mg BrdU/kg was applied by intraperitoneal injection 
to pregnant mice at indicated stages. Embryos were removed at E19.5 and fresh frozen brain 
sections were prepared. After postfixation and PBS wash, sections were incubated in 2 M 
HCl for 1h at 37°C. Afterwards, sections were washed 3 x in PBS and incubated for 10 min in 
borate buffer (0.1 M, pH 8.5) at room temperature. Sections were then washed 3 x with PBS 
and processed for immunohistochemistry as described. 
 
DNA quantification 
DNA was quantified in tissue homogenates as previously described [94]. Briefly, whole 
brains were homogenized by Polytron for 20 s at low strength in detection buffer (0.05 M 
NaPO4, 2.0 M NaCl, 2 mM EDTA, 1 μg/ml Hoechst 33258 (Sigma), pH 7.4), followed by 
sonication for 20 s. Samples were excited at 356 nm and emission at 492 nm was 
determined. DNA concentration of homogenates was determined relative to a standard curve 
using calf thymus DNA (Sigma). 
 
Neurospheres 
Neurospheres were prepared from P0 telencephali. Briefly, telencephali were dissected in 
HBSS, the meninges and the olfactory bulbs were removed. The tissue was triturated with a 
1 ml pipette tip in neurosphere medium consisting of DMEM/F12 (1:1), 0.2 mg/ml L-
glutamine, 1% penicillin/streptomycin, 2% B27, 2 μg/ml heparin, 20 ng/ml EGF and 10 ng/ml 
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FGF2. The homogenate was diluted twice in the ratio 1:1 with fresh neurosphere medium 
and each time triturated shortly. 5X104 cells were plated in a 5 cm dish. After 7 days, cultures 
were collected, and passaged. For determination of the capacity of secondary neurosphere 
formation and growth, cells were plated at a clonal density of 3000 cells/ml [121]. Six 
representative images were taken for each well of a 6-well plate to count neurospheres and 
measure the diameter. For differentiation, neurospheres were splitted after 5 to 6 days and 
plated on coverslips coated with 15 μg/ml Poly-L-Ornithin and 40 μg/ml Laminin at a density 
of 150,000 cells/cm². The dispersed cultures were differentiated in neurosphere medium 
lacking FGF2, EGF and Heparin and fixed after 5 days with 4% PFA. For staining, cells were 
washed 3 x with PBS, incubated for 10 min in 0.25% TritonX and then blocked for 30 min in 
PBS containing 5% BSA. Staining was performed with the same procedure as described 
above for the brain sections. 
 
 
 
 
 
 
 
 
 
 
 
 
  27
3.1.6. Figures and tables 
 
 
 
 
Figure 1: Generation of RAbKO mice. (A) Schematic representation of the wild-type (raptor wt) and 
targeted raptor allele before (raptor floxed) and after (raptor ko) expression of Cre recombinase from 
the Nestin promoter in CNS cells. Localization of PCR primers P1, P2 and P3 used in (B) are 
indicated. (B) Analysis of recombination in brain and tail lysates of newborn RAbKO (raptorfl/fl;Nes-
Cre+/-) and control (raptorfl/fl;Nes-Cre-/-) mice. The recombined raptor ko allele (PCR product of P1 and 
P3, first lane) is only found in the brain of mice that are positive for the Cre recombinase under the 
Nestin promoter (Cre, third lane). The raptor floxed allele signal (PCR product of P1 and P2, second 
lane) is strongly decreased in RAbKO brain lysates. The residual signal indicates occurance of 
unrecombined non-CNS cells in the brain. The rictor allele served as loading control. (C) Schematic 
representation of the impaired mTORC1 in knockout cells. Western blots of brain lysates of RAbKO 
and control mice probed for members of mTORC1 and mTORC2 and downstream signaling. 
Phosphorylation of S6 is strongly decreased in RAbKO lysates. (D) Photographs of newly born control 
and RAbKO mice are shown in the top panel. The lower panel shows the body weight of E19.5 control 
(dark grey), heterozygous RAbKO (light grey) and RAbKO mice (white). Bars (D) represent means ± 
standard deviation. 
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Figure 2: raptor deficient brains are smaller than control brains due to reduced cell size and 
defects in proliferation. (A) Brain weight of control (dark grey), heterozygous RAbKO (light grey) and 
RAbKO (white) mice. (B) Nissl staining of control and RAbKO brain sections at different rostro-caudal 
levels reveals that all major structures are evenly reduced in size. (C and D) Both, a decreased cell 
number and size contribute to decreased brain size. Determination of DNA amount (C) and 
concentration (D) in control (dark grey), heterozygous RAbKO (light grey) and RAbKO brains (white). 
(E) Representative micrographs of control and RAbKO neurosphere cultures. (F) Distribution of 
diameters of control (dark grey) and RAbKO (white) neurospheres. Size distribution of RAbKO 
neurospheres is strongly shifted to the left. Inset: box plot of the same data. The bottom and the top of 
the boxes represent the lower and the upper quartile, the middle band represents the median. 
Whiskers represent minimum and maximum. (G) Number of control (dark grey) and RAbKO (white) 
neurospheres per visual field. Bars (A, B, C, D and G) represent means ± standard deviation. n (A and 
B) = 22 (control), 9 (heterozygous RAbKO) and 8 (RAbKO). n (C and D) = 5 (control), 5 (heterozygous 
RAbKO) and 4 (RAbKO). n (F) = 100 (control), 91 (RAbKO). n (G) = 18 (control), 15 (RAbKO). p-
values (from two-tailed t-Test): ** p < 0.01, *** p < 0.001, ns: p > 0.05. Scale bars: (B) = 1 mm, (E) = 
100 µm. 
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Figure 3: Astrocytic differentiation is impaired in RAbKO brains. (A) Western blot analysis of 
brain lysates from control and RAbKO brains probed for indicated markers of neural development and 
β-Actin as loading control. (B) Upper part: Cresyl violet stainings of brain sections. Red boxes 
represent regions shown below. Micrographs show dentate gyrus and midline glial structure regions of 
control and RAbKO brain sections stained with GFAP antibody (red) and DAPI (blue). IGG: indusium 
griseum glia; MZG: midline zipper glia; GW: glial wedge. (C) Western blot analysis of protein 
concentration adjusted control and RAbKO lysates probed for Stat3 and its different phosphorylation 
states. Detection of β-Actin serves as loading control. (D) Micrographs of differentiated neurosphere 
derived cells form control and RAbKO, stained with β-tubulin III antibody (red), GFAP antibody (green) 
and DAPI (blue). (E) Quantification of the fraction of neurons (upper panel) and astrocytes (lower 
panel) in percent of control. (F) Western blot analysis of lysates from cultures grown under the same 
conditions as in (D) probed for the indicated markers. n (E) = 3 control and 3 RAbKO. p-values (from 
paired t-Test): ** p < 0.01, ns: p > 0.05. Scale bars: (B) = 200 µm, (D) = 100 µm. 
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Figure 4: Defects in hippocampal layering. (A) Micrographs of cresyl violet stained and Map2 
(green)/DAPI (blue) or NeuN (red)/DAPI (blue) costained E15.5 and E19.5 RAbKO and control 
hippocampus. Asterisks depict the position of the hylus which is filled with NeuN-positive cells in 
RAbKO sections, arrows the region of the developing granular cell layer, which is distinctly formed 
only in the control. The filled arrowhead points towards the fading of the SP in RAbKO. Open 
arrowheads point to the pyramidal layer (control) or the place where the pyramidal layer is missing 
(RAbKO). CA1, CA3, dentate gyrus (DG) and cortical plate (CP) and hippocampal plate (HP) are 
indicated. (B) BrdU (red)/DAPI (blue) staining of brain sections of E19.5 embryos which incorporated 
BrdU at E14.5.  The arrow depicts the ectopic layer of BrdU-positive cells in the RAbKO hippocampus. 
Scale bars (A,B) = 200 μm. 
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Figure 5: Defects in cortical layering. (A) Cresyl violet staining of RAbKO and control cortices. (B) 
Map2 (green)/DAPI (blue) stainings of RAbKO and control cortices. (C) NeuN (red)/DAPI (blue) 
stainings of RAbKO and control cortices. (D) BrdU was injected into pregnant dams at E14.5 of 
embryonic development and brain sections prepared from E19.5 embryos. BrdU (red)/DAPI (blue) 
staining shows a difference in the distribution of newly formed cells. (E) Quantification of the 
distribution of BrdU-positive cells. The first two panels show the percentage of BrdU-positive cells in 
VZ/IZ and in the CP, respectively. The last panel shows the ratio of BrdU-positive cells found in the CP 
in relation to the cells located in the VZ/IZ. MZ: marginal zone; CP: cortical plate; SP: subplate; IZ: 
intermediate zone; VZ: ventricular zone. Scale bars (A,B,C,D) = 100 μm.  
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Figure 6: Several axon tracts are smaller in raptor-deficient brains and dendritic complexity is 
reduced in culture. (A) Micrographs of indicated axon tracts of comparable sections stained with 
cresyl violet. (B) Quantifications of control (dark grey) and RAbKO (white) corpus callosum (CC) 
thickness, which was normalized to dorsoventral axis length of the section and anterior commissure 
(AC) area, which was normalized to section area. (C) Western blots of cortical lysates of control and 
RAbKO brains probed with the neuronal marker β-tubulin III and β-Actin as control. (D and E) 
Hippocampal neurons double floxed for raptor were cultured from E16.5 embryos and cotransfected at 
4 DIV with either a Cre expressing plasmid or a control vector together with a GFP expressing 
plasmid. Neurons were fixed at 14 DIV and analyzed by confocal microscopy. (D) Representative 
images from control and Cre-transfected neurons. Scale bars, 50 μm. (E) Sholl analysis of knockout 
and control neurons. Concentric circles of indicated radius were drawn around the soma. The number 
of crossing dendrites was determined for each circle. n (B) = 5 (control) and 4 (RAbKO). p-values 
(from two-tailed T-test): * p < 0.05,  ** p < 0.01. Error bars in (E) are confidence intervals. Scale bars in 
(A) CC: 0.5 mm; AC: 100 µm; Fimbrium: 250 µm. Scale bars in (D): 50 μm. 
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3.2.1. Summary 
 
Mammalian Target of Rapamycin (mTOR) is a central controller of cell growth. mTOR 
assembles into two distinct multiprotein complexes called mTOR complex 1 (mTORC1) and 
mTORC2. Here we show that the mTORC1 component raptor is critical for muscle function 
and prolonged survival. In contrast, muscles lacking the mTORC2 component rictor are 
indistinguishable from wild-type controls. Raptor-deficient muscles become progressively 
dystrophic, are impaired in their oxidative capacity and contain increased glycogen stores, 
but express structural components indicative of oxidative muscle fibers. Biochemical analysis 
indicates that these changes are probably due to loss of activation of direct downstream 
targets of mTORC1, downregulation of genes involved in mitochondrial biogenesis, including 
PGC1α, and hyperactivation of PKB/Akt. Finally, we show that activation of PKB/Akt does not 
require mTORC2. Together, these results demonstrate that muscle mTORC1 has an 
unexpected role in the regulation of the metabolic properties and that its function is essential 
for life.  
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3.2.2. Introduction 
 
Growth of an organ during development and during adaptation in the adult can be controlled 
by alterations either in the number or the size of cells. The two mechanisms are 
fundamentally different and require distinct regulation. Rapamycin is a cell growth inhibitor 
used to treat a number of clinical indications including graft rejection and cancer [122]. The 
molecular target of rapamycin is a Ser/Thr kinase, called TOR in yeast [8] or mTOR in 
mammals. The evolutionarily conserved TOR pathway controls many cellular processes, 
including protein synthesis, ribosome biogenesis, nutrient transport and autophagy (reviewed 
in [16]). mTOR assembles into two distinct multiprotein complexes, termed mTORC1 and 
mTORC2 [12, 13]. mTORC1 consists of raptor (regulatory associated protein of mTOR), 
mLST8, PRAS40 and mTOR [16], and is sensitive to rapamycin. mTORC2 consists of rictor 
(rapamycin insensitive companion of mTOR), mSIN1, mLST8 and mTOR [12, 13]. 
Changes in the size of adult muscle, in response to external stimuli, are mainly due to the 
growth of individual muscle fibers and not an increase in fiber number [55]. As mTOR 
controls cell growth, it has also been implicated in the control of muscle mass. For example, 
rapamycin inhibits recovery of skeletal muscle from atrophy [64]. Moreover, activation of the 
mTORC1-upstream component PKB/Akt induces muscle hypertrophy [64, 65, 123] and this 
increase is rapamycin-sensitive [60]. Conversely, muscle fibers of mice deficient for the 
mTOR downstream target S6 kinase 1 (S6K1) are atrophic [59]. In contrast, little is known of 
the function of rapamycin-insensitive mTORC2 whose primary readouts are thought to be the 
organization of the actin cytoskeleton. Moreover, mTORC2 has been shown to be the kinase 
that phosphorylates PKB/Akt on Ser473 [45].  
To circumvent the early embryonic lethality of mice deficient for raptor or rictor [84, 124], we 
generated mice with floxed raptor or rictor alleles. Here we describe the phenotype of mice 
that lack raptor (i.e. mTORC1), rictor (i.e. mTORC2) or both proteins specifically in skeletal 
muscle. We find that deletion of mTORC2 does not cause an overt muscle phenotype. In 
contrast, mTORC1-deficient muscles manifest signs of atrophy and become progressively 
dystrophic. Moreover, muscles behave metabolically like fast-twitch, glycolytic skeletal 
muscle, but exhibit structural features and contraction properties indicative of slow-twitch, 
oxidative muscle fibers. Biochemical analysis indicates that this phenotype can be accounted 
for by the absence of phosphorylation of the immediate mTORC1 downstream targets 
S6K/S6 and 4EBP1, the downregulation of PGC1α, and hyperphosphorylation of PKB/Akt. 
Finally, deficiency of both raptor and rictor results in a phenotype indistinguishable from that 
of muscles lacking only raptor. Importantly, PKB/Akt is still hyperphosphorylated under these 
conditions, suggesting that mTORC2 is not the only kinase able to phosphorylate PKB/Akt on 
Ser473.  
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3.2.3. Results 
 
Skeletal muscle-specific ablation of raptor and rictor  
To examine the function of raptor and rictor in skeletal muscle we used the Cre-loxP 
recombination system. To this end, we introduced loxP sites into the raptor and the rictor 
locus (Figure 1A). In both cases, Cre-mediated recombination causes a frame shift and early 
stop of translation. In addition, FRT sites were inserted that flanked a neomycin resistance 
cassette for the selection of targeted embryonic stem (ES) cells. This cassette was removed 
using Flp deleter mice (Figure 1A; [125]). Southern blot analysis confirmed successful 
targeting in ES cells and germ line transmission of resulting chimeras (Figure 1B). Mice 
homozygous for the floxed allele (raptorfl/fl or rictorfl/fl) were mated with heterozygous floxed 
mice that also expressed Cre recombinase under the control of the muscle-specific human 
skeletal actin (HSA) promoter [87]. Mice positive for the HSA-Cre transgene that also carried 
two floxed alleles were then analyzed. For simplicity, we refer to HSA-Cre; raptorfl/fl as 
RAmKO (for raptor muscle knockout) and to HSA-Cre; rictorfl/fl as RImKO (for rictor muscle 
knockout) mice. Successful recombination of raptor or rictor was confirmed by PCR on 
genomic DNA isolated from tibials muscle (Figure S1A). Western blot analysis of RAmKO 
and RImKO skeletal muscle revealed a strong reduction of the respective proteins (Figure 
1C; Figure S1B and Table S1). Residual expression of these proteins in knockout muscle is 
not due to leaky recombination of the targeted allele as raptorfl/fl or rictorfl/fl mice crossed to 
other Cre-expressing mice led to a complete loss of the respective protein in the targeted 
tissue (Figure S1B; [90]; M.N. Hall, personal communication). Thus, the low levels of raptor 
and rictor protein that were detected in the RAmKO and RImKO muscles are ascribable to 
the expression of raptor or rictor in non-targeted cells, such as fibroblasts, satellite cells, 
Schwann cells and peripheral nerves, which are also contained in skeletal muscle. 
Neither RAmKO nor RImKO mice showed an overt phenotype in the first weeks of life. 
Starting at the age of approximately 5 weeks, RAmKO mice could be distinguished from their 
littermates by their lower body weight. The difference became significant after day 63 and the 
mice remained lighter throughout life (Figure 1D). In contrast, the body weight of RImKO 
mice did not differ significantly from controls, although at higher age RImKO mice were 
slightly heavier (Figure 1D). For both RAmKO and RImKO mice, the food consumption was 
comparable to controls (Figure S1C and data not shown). RAmKO mice developed a 
pronounced kyphosis starting at the age of approximately 2 months and became markedly 
lean (Figure 1E; Figure S1D). In contrast, RImKO mice appeared normal. Finally, RAmKO 
mice began to die at the age of 110 days and none survived for more than 190 days (Figure 
1F). RImKO mice did not die prematurely (the oldest RImKO mice now being more than 2 
years old). 
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To examine whether the difference in weight gain was based on reduced muscle mass in 
RAmKO mice, we weighed different muscles and several other organs at day 90 (i.e. before 
the mice showed a severe phenotype) and at day 140. As shown in Table 1, all the muscles 
measured were significantly lighter in 90 and 140 day-old RAmKO mice compared to 
controls. As RAmKO mice appeared lean (Figure 1E) and only little or no fat was detected in 
older mice (Figure S1D), we also weighed the epididymal fat pads. Indeed, RAmKO mice 
contained significantly less adipose tissue at the age of 140 days (Table 1). The loss of 
adipose tissue does not seem to be due to changes in mitochondrial uncoupling properties 
as the body temperature of RAmKO mice was not different from control littermates (Figure 
S1E). The weight of the liver was indistinguishable from controls whereas hearts were again 
lighter (Table 1). The left ventricle mass of the heart, however, correlated with the difference 
in body weight (Figure S1F), indicating that the difference in heart weight is probably due to 
allometric scaling [126]. Moreover, the ejection fraction determined by echocardiography was 
indistinguishable from littermate controls (data not shown). Finally, we could not detect any 
recombination events in the hearts of RAmKO mice (Figure S1A). Our data therefore show 
that raptor deficiency in skeletal muscle causes a progressive, disproportional loss of skeletal 
muscle and fat. 
 
Deficiency of mTORC1 but not mTORC2 causes muscle dystrophy 
Kyphosis and early death are often signs of muscle dystrophy [127]. We therefore examined 
different skeletal muscles of RAmKO and RImKO mice using hematoxylin & eosin (H&E) 
staining. No change in the overall architecture of soleus and extensor digitorum longus (EDL) 
muscle was found in RImKO mice (Figure 2A). Muscles from RAmKO mice showed signs of 
a dystrophy, such as mononuclear cells (green arrowheads) and a high number of small and 
large muscle fibers (blue arrowheads). In soleus muscle and to a lower extent in EDL, we 
also found muscle fibers with centralized nuclei (white arrowheads), indicative of ongoing de- 
and regeneration, and structures reminiscent of central cores (black arrowheads in Figure 2A 
and Figure 2B). Quantification showed that the fiber size distribution was strongly altered in 
both soleus and EDL muscle (Figure 2C, D, E, F). In addition, the number of centralized 
myonuclei (Figure 2G) and the relative percentage of muscle fibers with the central core-like 
structures (Figure 2H) was higher in RAmKO mice compared to controls. Dystrophic 
hallmarks seemed more pronounced in soleus than in EDL muscle. Interestingly the severity 
of the dystrophy correlated with the high endogenous expression of raptor, rictor, mTOR or 
PKB/Akt in wild-type soleus muscle (Figure S2A). Muscles of RAmKO mice also showed 
increased immunoreactivity for tenascin-c and f4/80 (Figure S2B), which mark fibrotic tissue 
[128] and infiltrating macrophages [129], respectively. However, other dystrophic hallmarks 
including increased uptake of Evans blue into muscle fibers and increased levels of creatine 
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kinase in the blood could not be detected (Figure S2C and data not shown). Similarly, the 
number of muscle fibers was not changed in soleus muscle of RAmKO mice compared to 
controls (Figure S2D). Neuromuscular junctions of RAmKO mice were indistinguishable from 
those in control mice (Figure S2E). Probably due to ongoing de- and regeneration, many 
extrasynaptic acetylcholine receptor (AChR) clusters could be detected in the diaphragm of 
RAmKO mice (Figure S2F). Based on the extensive muscle wasting and the high degree of 
fibrosis, the dystrophy was particularly severe in the diaphragm of older mice (Figure 2I), 
suggesting that respiratory failure might be the cause of premature death. In contrast to 
RAmKO mice, muscles of RImKO mice did not show any alterations in fiber size (Figure 
S3A) and in the cytoskeletal organization as indicated by the sarcomeric arrangement of α-
actinin (Figure S3B). In summary, our data show that ablation of raptor and thus of mTORC1, 
but not of rictor, results in a progressive muscle dystrophy.  
 
Skeletal muscles of RAmKO mice show alterations in their metabolic and structural 
properties 
One of the first observations we made during the course of this work was that muscles of 
RAmKO mice appeared paler than those of RImKO or control mice. This difference was 
particularly striking for the soleus muscle (Figure 3A, arrowhead) and was not based on 
decreased vascularization, as revealed by staining for laminin-α5 (data not shown), which is 
expressed in blood vessels [130]. To test for changes in mitochondrial function, we used an 
NADH-tetrazolium (NADH-TR) staining. Indeed, the activity of oxidative enzymes appeared 
lower in both, EDL and soleus muscle of RAmKO mice (Figure 3B). Fibers with central core-
like structures, which were completely devoid of NADH-TR reactivity, could be found in 
RAmKO soleus muscle (black arrowheads). Such a lack of NADH staining is a diagnostic 
feature of central core disease [131]. To further test whether the changes in NADH-TR 
reactivity involved mitochondria, we also examined longitudinal sections of soleus muscle by 
electron microscopy. Muscle of RAmKO mice was distinguishable from control muscle by a 
substantial loss of intermyofibrillar mitochondria, which are normally localized perpendicular 
to the Z disks (arrows in upper panel, Figure 3C). Only few intermyofibrillar mitochondria 
remained (arrow lower panel, Figure 3C). Moreover, mitochondria localized in the 
subsarcolemmal space seemed more densely packed and swollen in RAmKO mice (Figure 
S4A). As a decrease in oxidative properties is often accompanied by a compensatory 
increase in glycolytic activity, we performed a periodic acid Schiff (PAS) staining. Indeed, the 
glycogen content was increased in both EDL and soleus muscle (Figure 3D). The increase 
was more pronounced in the fast-twitch EDL muscle. The glycogen content in the 
gastrocnemius muscle, which consists of a mixed population of fast- and slow-twitch fibers, 
was more than 5 times higher than in control mice (control: 21 ± 7 µmol glucose/g tissue; 
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RAmKO: 108 ± 22 µmol glucose/g tissue; mean ± SEM; N = 4 mice). The change in oxidative 
capacity and glycogen content in skeletal muscle also affected overall metabolism as 
glucose uptake from the blood was significantly slower in RAmKO mice compared to 
littermate controls (Figure 3E).  
High content of glycogen is indicative of fast-twitch (type II) muscle fibers. To test whether 
muscles in RAmKO mice also changed their structural properties, we stained EDL and 
soleus muscle for the slow myosin heavy chain (slMHC), a marker of slow-twitch fibers. 
Surprisingly, EDL and soleus muscle of 140 day-old RAmKO mice contained even more 
slMHC-positive muscle fibers (Figure 3F; green) than controls and the increase of slMHC 
was regionalized in individual muscles (Figure S4B). In both muscles, the number of slMHC-
positive fibers was approximately 2 to 3 times higher than in controls (Figure 3G & H). In 
soleus muscle of RAmKO mice, almost 100% of the fibers were positive for slMHC (Figure 
3H) and this increase was also seen by Western blot analysis (Figure 3I; Table S1). 
Moreover, other components characteristic for slow-twitch muscle, such as the slow isoform 
of troponinT (slTnT) and of troponinI (slTnI), were also increased in soleus muscle of 
RAmKO mice (Figure 3I & J; Table S1). Thus, deletion of mTORC1 in skeletal muscle fibers 
causes a shift of their metabolic properties from oxidative to glycolytic. However, this change 
in the metabolic characteristics of muscles is opposite to their structural properties.  
 
Functional characterization of muscles in RAmKO mice 
To address whether the observed changes in metabolic and structural characteristics had 
consequences on the overall performance of muscle, we allowed 90 day-old mice to exercise 
using voluntary wheel running. The representative activity chart of a single mouse shows that 
running sessions of RAmKO mice were shorter and less frequent than those of controls 
(Figure 4A). When averaged over one week, the total distance run per day by RAmKO mice 
was ~ 60% of that of control mice (Figure 4B) and the top running speed was significantly 
lower (Figure 4C). In contrast to the aerobic wheel running task, RAmKO mice performed 
equally well as control animals in a grip strength test on a horizontal grid (Figure 4D). To 
examine the contraction properties of muscles, force measurements were performed on 
isolated EDL and soleus muscles. In line with the observed increase of fibers expressing 
structural proteins characteristic of slow-twitch muscle, time to peak, half time to peak and 
relaxation time of the twitch were all increased (Table 2). This difference to control mice did 
not reach significance in EDL muscle but was highly significant in soleus muscle (Table 2). 
Twitch force and maximal tetanic absolute force for both muscles was, however, significantly 
lower in RAmKO mice. The decrease of absolute force capacity reflects the decrease of 
muscle mass (Table 1), since there is no difference of the maximal tetanic force when 
normalized to the muscle cross-sectional area (Table 2). An intermittent maximal tetanic 
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stimulation protocol revealed that both EDL and soleus muscle from RAmKO mice were 
more resistant to fatigue (Figure 4E). These data indicate that raptor-deficient muscle fibers 
have a reduced aerobic capacity (voluntary wheel running) like fast-twitch, glycolytic muscle 
fibers, but exert contraction properties (isolated muscles) of slow-twitch, oxidative muscle 
fibers.  
 
Inactivation of raptor or rictor affects activation of PKB/Akt 
In search of a mechanistic explanation for the phenotypes, we examined soleus muscle of 
RAmKO and RImKO mice biochemically. In each experiment, at least three different mice 
were compared with three littermate controls. Deletion of raptor or rictor did not significantly 
affect the levels of mTOR (Figure 5A, Table S1). The levels of rictor were not lowered in 
RAmKO mice and there was a slight decrease of raptor in RImKO mice (Figure 5A, Table 
S1). The amount of S6K, S6 and 4EBP1, which are the main targets of mTORC1, was not 
changed in RAmKO mice. However, phosphorylation of S6 and 4EBP1 was strongly 
decreased (Figure 5A; Table S1). In RImKO mice, mTORC1 targets were not changed but 
the level and activation state of PKB/Akt and PKCα, which are both well characterized 
substrates of mTORC2 [13, 45], were lower. More importantly, phosphorylation of PKB/Akt 
on residues Thr308 and Ser473 was strongly increased in RAmKO mice (Figure 5A; Table 
S1). Furthermore, the total amount of FoxO1 and FoxO3a was increased in RAmKO mice 
concomitant with an increase in phosphorylation of FoxO1 on Thr24 (Figure 5A; Table S1). In 
contrast, phosphorylation of FoxO1 on Ser316 and of FoxO3a on Thr32 was not increased.  
Activation of S6K by mTORC1 causes feedback inhibition of the insulin/IGF1 pathway by 
affecting the levels and the phosphorylation of IRS-1 [132, 133]. Consistent with this notion, 
deficiency of mTORC1 and thus absence of S6K/S6 activation abrogated this inhibitory 
feedback and strongly increased IRS-1 levels in muscles of RAmKO mice (Figure 5B; Table 
S1). Concomitant with the high protein levels, IRS phosphorylation on Ser636 and Ser639 
was increased. On the other hand, both the levels and phosphorylation of the mitogen-
activated protein kinase Erk1 and Erk2 were not significantly changed (Figure 5B; Table S1). 
Thus, activation of PKB/Akt is probably due to the failure of raptor-deficient muscle fibers to 
activate S6K and thus due to the absence of the inhibitory feedback onto IRS. The release of 
this feedback in muscle may require prolonged inactivation of mTORC1 as phosphorylation 
of PKB/Akt was not increased after 8 hour treatment of cultured C2C12 myotubes with 
rapamycin and was only slightly elevated after 16 hours (Figure S5C).  
Next we asked whether part of the phenotype of RAmKO mice could be based on this 
hyperphosphorylation of PKB/Akt. To determine whether PKB/Akt was indeed activated 
within muscle fibers and not in non-muscle tissue of RAmKO mice; we stained cross-sections 
of soleus muscle with antibodies specific for PKB/Akt phosphorylated on Ser473 (P-
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PKB/AktS473). Indeed, many of the muscle fibers were strongly positive for P-PKB/AktS473 
(Figure S5A). Akt/PKB has been shown to regulate expression of atrogenes, called atrogin-
1/MAFbx and MuRF-1, via the FoxOs [67, 134]. As expected, mRNA levels for both 
atrogenes were significantly lower in RAmKO mice than in controls (Figure 5C). A further 
target of PKB/Akt is glycogen synthase kinase3β (GSK3β), which in turn inhibits glycogen 
synthase [135]. Whereas the amount of GSK3β was unaffected, phosphorylation of Ser9 was 
significantly increased (Figure 5C; Table S1). Moreover, glycogen phosphorylase, which is 
the enzyme that generates free glucose from glycogen, was downregulated (Figure 5C; 
Table S1). Thus, hyperphosphorylation of PKB/Akt in conjunction with downregulation of 
glycogen phosphorylase is probably the basis for the increased levels of glycogen observed 
in RAmKO mice.  
In an attempt to identify the pathway that might underlie the increased number of muscle 
fibers expressing slMHC, we found a slight increase in the levels of calcineurin and a highly 
significant increase in myocyte-enhancer factor 2A (Mef2A; Figure 5C; Table S1). A slight, 
but not significant increase in Mef2D was also observed. The increase in Mef2A is not a 
consequence of the ongoing de- and regeneration in soleus muscle as Mef2A was also 
increased in the least affected EDL muscle (Figure S5B). In contrast to skeletal muscle in 
vivo, Mef2A and slMHC were not increased in cultured C2C12 myotubes upon prolonged 
treatment with rapamycin (Figure S5C). 
 
Genes involved in mitochondrial biogenesis are downregulated in RAmKO mice 
One of the most striking features of RAmKO skeletal muscle is its lower oxidative capacity 
that is probably due to ultrastructural changes and loss of mitochondria. Thus, we also tested 
whether genes involved in mitochondrial biogenesis were affected by the deletion of raptor. 
Recent evidence indicates a function of mTORC1 in the regulation of mitochondrial function 
via PGC1α [42]. Consistent with these findings, transcript levels for PGC1α and for its target 
gene myoglobin were significantly reduced in RAmKO muscle (Figure 5E). Moreover, the 
protein levels of the PGC1α co-activator PPARγ and the mitochondrial marker cytochrome c 
oxidase IV (COX IV) were significantly decreased in RAmKO mice (Figure 5F; Table S1). 
These results are consistent with the low oxidative capacity of muscle from RAmKO mice 
and they support the notion that this is due to loss of PGC1α.  
 
Activation of PKB/Akt is independent of mTORC2 
To test whether the hyperactivated state of PKB/Akt in RAmKO mice can be prevented by 
additional deletion of rictor, we generated double floxed mice and mated those with HSA-Cre 
mice. The resulting mice, called DmKO, lacked both raptor and rictor in skeletal muscle 
(Figure 5G; Table S1). Their overall phenotype was indistinguishable from RAmKO mice 
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(data not shown). Like in RAmKO mice, skeletal muscle of DmKO mice contained high levels 
of glycogen and was less oxidative (Figure 5H). Levels of mTOR were significantly lower in 
DmKO mice than in either of the single knockouts (Figure 5G; Table S1). As mTORC2 was 
shown to phosphorylate PKB/Akt on Ser473 [45], we also tested the activation state of 
PKB/Akt in DmKO muscle. As shown in Figure 5G and in Table S1, PKB/Akt was still 
hyperphosphorylated on Thr308 and Ser473 in DmKO mice. Again, phosphorylation of 
PBK/Akt occurred only in muscle fibers and not in non-muscle tissue (Figure 5J). In 
summary, these results indicate that mTORC2 is not the only kinase that phosphorylates 
PKB/Akt on Ser473.  
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3.2.4. Discussion 
 
Our work dissects the role of raptor and rictor (i.e. mTORC1 and mTORC2, respectively) in 
skeletal muscle. The HSA-Cre mice used for our experiments start to express Cre at the 
earliest stages of skeletal muscle development when the first myotubes are formed. In fully 
developed muscle, Cre is exclusively expressed in skeletal muscle fibers but not in non-
muscle cells, such as Schwann cells, fibroblasts or satellite cells [87]. Neither RAmKO nor 
RImKO mice showed any abnormalities at birth, indicating that mTORC1 and mTORC2 are 
not essential for muscle development. Whereas no overt phenotype was detected in RimKO 
mice throughout adulthood, which is consistent with another report [136], RAmKO mice 
developed a progressive dystrophy and ultimately died around the age of five months. 
Interestingly, DmKO mice showed very similar pathological changes as RAmKO mice, 
indicating that mTOR function in skeletal muscle requires only mTORC1.  
The dystrophy in RAmKO mice did not affect all muscles to the same extent. For example, 
diaphragm and soleus muscles were severely affected while EDL showed much less 
changes. Prominent features of the dystrophy were elevated numbers of muscle fibers with 
centralized nuclei and the presence of central core-like structures. Central cores are 
hallmarks of “central core diseases”, which are inherited neuromuscular disorders with a 
myopathic syndrome. The most frequent causes of this group of diseases are mutations in 
the ryanodine receptor, which is the main protein responsible for calcium homeostasis in 
muscle (reviewed in [137]). Thus, the similarity of the pathology in RAmKO to this class of 
disease suggests that mishandling of intracellular calcium may underlie the disease. The low 
levels of PGC1α may additionally contribute to the dystrophic phenotype of RAmKO mice as 
conditional ablation of PGC1α in skeletal muscle results in a myopathic phenotype [138]. 
Finally, several metabolic diseases that cause accumulation of glycogen in skeletal muscle, 
such as Pompe’s and McArdle’s disease, affect skeletal muscle function. The most severely 
affected patients may even die because of respiratory distress [139]. In summary, RAmKO 
show changes in muscle homeostasis that together may lead to the progressive muscle 
dystrophy. 
 
Raptor is required for high oxidative capacity of skeletal muscle  
We found that the severity of the muscle dystrophy correlated with the relative levels of 
raptor, rictor, mTOR and PKB/Akt in particular muscles. Interestingly, the most affected 
muscles, such as soleus or diaphragm, are also those that are insulin-sensitive [140] and 
contain a high number of slow-twitch, oxidative fibers. Biochemical and morphological 
analysis showed that soleus muscle expressed little of the oxygen carrier myoglobin and of 
COXIV, and contained fewer and misshaped mitochondria. A direct role of mTOR and raptor 
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for the function of mitochondria has recently been suggested using cultured Jurkat cells 
[141]. Moreover, mTOR has been shown to form a complex with PGC1α [42], which together 
with its cofactor PPARγ is a key regulator of mitochondrial biogenesis and function. 
Consistent with a regulatory function of mTORC1 for mitochondria, mRNA levels for PGC1α 
and protein levels of PPARγ were decreased in RAmKO mice. Furthermore, mRNA and 
protein levels of target genes for PGC1α/PPARγ, such as myoglobin [142] and glycogen 
phosphorylase [143] were also reduced in RAmKO mice. Also, very similar to the phenotype 
of RAmKO mice, a reduced intermyofibrillar mitochondrial content in slow-twitch muscles has 
been reported in PGC1α knockout mice [144]. In summary, our data indicate that mTORC1 is 
essential for the function of mitochondria in skeletal muscle and they link mTORC1 to the 
regulation of PGC1α in vivo. 
 
Segregation of metabolic and structural properties in skeletal muscle of RAmKO mice 
Despite the loss of oxidative capacity and the downregulation of PGC1α, expression of slow 
structural proteins (slSP; Figure 5K) was increased in RAmKO mice. Analysis of the 
mechanical properties in EDL and soleus muscle further confirmed that both muscles adapt 
characteristics indicative of slow-twitch fibers. These results suggest that RAmKO mice 
induce a structural program for slow-twitch fibers. As muscle-specific inactivation of PGC1α 
causes a fiber-type switch to fast-contracting muscle fibers [138] and transgenic 
overexpression causes an increase in oxidative muscle [142], we also tested whether any 
other pathways that affect muscle differentiation were altered in the RAmKO mice. Besides 
PGC1α, the best characterized factors involved in fiber type determination are 
calcineurin/NFAT and the Mef2 transcription factors [145]. Of those candidate genes, the 
levels of calcineurin and in particular of Mef2A and Mef2D were increased in RAmKO mice. 
Thus, facilitated Mef2-mediated transcription may be the basis for the increased levels of 
slSP despite the low levels of PGC1α. Opposite regulation of PGC1α and Mef2A has also 
been seen in cultured cells when treated with rapamycin [42]. Mef2 has also been show to be 
dominant in the regulation of muscle fiber type as transgenic overexpression of a 
constitutively active form of Mef2 is sufficient to increase the number of slow muscle fibers 
[146]. Mef2 is generally thought to be controlled by calcium-activated processes acting via 
calcineurin and CaM kinase IV [147]. In this context it is interesting to note that the increase 
of the half-relaxation time in RAmKO muscles may result from a lower removal rate of 
calcium from the myoplasm by the sarcoplasmic reticulum [148]. This prolonged presence of 
intracellular calcium during contractile activity might contribute to the activation of calcium-
dependent signaling pathways, and thus to the upregulation of slSP (Figure 5K). On the 
other hand, it is possible that Mef2 expression is increased because of hyperactivation of 
PKB/Akt [149]. Consistent with this notion, failure to induce a pronounced phosphorylation of 
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PKB/Akt in cultured C2C12 myotubes by treatment with rapamycin coincided with unchanged 
levels of Mef2A and slMHC (Figure S5C).  
 
Raptor deficiency affects protein synthesis directly and PKB/Akt activation indirectly 
Ablation of mTORC1 in skeletal muscles prevented phosphorylation of S6K/S6 and 4EBP1. 
This branch of the mTOR signaling pathway is characterized best and has been shown to 
directly control protein synthesis. Impaired efficacy of protein synthesis in postnatal muscle 
might also be the reason for the muscles being lighter in RAmKO mice. This effect may also 
contribute to the shift in fiber size distribution towards smaller values. Our data thus implicate 
mTORC1 in the maintenance of mass even in fully innervated muscle. Therefore, they 
extend previous results in which mTOR inhibition by rapamycin was shown to prevent 
compensatory hypertrophy and recovery from atrophy but not cause atrophy [64]. Our results 
are also consistent with the findings that skeletal muscles of S6K1-deficient mice are atrophic 
[59]. The difference in weight of the RAmKO mice became significant only after the age of 
approximately 2 months, suggesting that the absence of raptor might be compensated for 
during early periods of muscle growth. One compensatory mechanism could be PKB/Akt-
mediated phosphorylation of GSK3β as inhibition of GSK3β has been shown to cause 
hypertrophy in cultured C2C12 myotubes [150]. We also provide evidence that the lack of 
S6K activation in RAmKO mice is responsible for the hyperphosphorylation of PKB/Akt on 
Thr308 and Ser473 as levels of IRS-1 were highly increased. Activation of S6K has been 
shown to decrease the levels of IRS-1 (reviewed in [151]). Interestingly, the same 
hyperactivation of PKB/Akt is seen in mice with an adipocyte-specific ablation of raptor [90].  
 
Raptor-deficient skeletal muscles are small, despite high energy consumption 
Whereas changes in mitochondrial content and function might be based on a direct influence 
of mTORC1 (Figure 5K), other aspects such as the loss of adipose tissue are probably a 
consequence of the hyperactivation of PKB/Akt. Muscle-specific overexpression of a 
constitutively active form of PKB/Akt causes pronounced hypertrophy [60]. Concomitantly 
with the hypertrophy, mice are lean and do not become obese on a high fat diet [60]. In the 
RAmKO mice, PKB/Akt was hyperactive resulting in mice that had much less fat than control 
mice on a normal chow diet (Table 1) or on a high fat diet (KR, CFB and MAR, unpublished 
observation). In contrast to mice that express the constitutively active form of PKB/Akt, lack 
of mTORC1 prevented the "translation" of PKB/Akt activation into muscle hypertrophy in 
RAmKO mice, Thus, RAmKO mice behave metabolically like mice that overexpress activated 
PKB/Akt but lack the hypertrophic effect on muscle. We hypothesize that the metabolic 
phenotype of being lean is due to the high need of muscle for glucose because of their high 
glycogen storage capability and their low capacity for oxidative phosphorylation. If the muscle 
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of RAmKO mice acts as such a global glucose sink, non-muscle tissues may have to use 
alternative energy sources such as fatty acids. This, in turn, could result in an increased 
release and mobilization of fatty acids from adipose tissue. The high content of glycogen is 
probably based on the hyperactivation of PKB/Akt, which inhibits GSK3β, which in turn, 
releases inhibition of glycogen synthase (Figure 5H). In addition, inhibition of GSK3β also 
lowers phosphorylation of NFATc and thus prolongs its activity in the nucleus [152]. NFATc 
transcription factors, which are also targets of calcineurin (see above), are known to 
contribute to fiber type selection (reviewed in [153]). Thus, changes in NFATc activity may 
add to the expression of structural proteins indicative of slow-twitch muscle.  
 
Hyperactivation of PKB/Akt does not require rictor/mTORC2 
Our data strongly indicate that the absence of the S6K-mediated inhibitory feedback caused 
phosphorylation of PKB/Akt on Thr308 and Ser473 in RAmKO mice. While phosphorylation 
on Thr308 is mediated by 3-phosphoinositide-dependent kinase (PDK1; [154]), mTORC2 has 
been shown to phosphorylate PKB/Akt on Ser473 [155]. Consistent with such a role for 
mTORC2, we and others observed a decrease in Ser473 phosphorylation in mice deficient 
for rictor (Figure 5; [84, 124, 136]). We now show that unexpectedly, muscles from mice 
lacking both mTORC1 and mTORC2 still showed a marked increase in PKB/Akt 
phosphorylation on both Thr308 and Ser473. Thus, mTORC2 is not required to 
phosphorylate PKB/Akt on Ser473 in vivo, indicating that skeletal muscles express a PDK2 
distinct from mTORC2. A candidate for this kinase is DNA-dependent protein kinase (DNA-
PK), which has been shown to phosphorylate PKBα/Akt1 in cells that are deficient for rictor in 
response to DNA damage [156]. DNA-PK and PKB/Akt are localized in the nucleus of 
embryonic fibroblasts upon DNA damage [156]. However, PKB/Akt phosphorylated on 
Ser473 in DmKO mice was expressed along the sarcolemma and not specifically localized in 
myonuclei. Several additional proteins have been postulated to act as PDK2, some of which 
are expressed in skeletal muscle and are localized to the sarcolemma (see [155] for a 
review). 
In summary, our data show that mTORC1 is important for the function and maintenance of 
skeletal muscle. We provide evidence that the different aspects of the phenotype observed in 
RAmKO mice are probably based either on the direct effect of mTORC1 on its downstream 
targets S6K and 4EBP1, on the function of mTORC1 to regulate mitochondrial biogenesis 
and function via PGC1α, or on an indirect effect on its upstream component PKB/Akt. Our 
data also suggest that long-term treatment with high doses of rapamycin may have 
detrimental effects on muscle function.  
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3.2.5. Experimental procedures 
 
Antibodies 
Rabbit polyclonal antibodies: 4E-BP1 (Phas-I) from Zymed, ERK1&2 pan and ERK1&2 
(pTpY185/187) from Biosource, FoxO1a and FoxO1a (phospho S319) from Abcam, P-PKCα 
(Ser657) and Troponin T-SS (H-55) from Santa Cruz, Phospho-4E-BP1 (Ser65), PAN-actin, 
Akt, Phospho-Akt (Thr308), Pan-Calcineurin A, Phospho-FoxO1 (Thr24)/ FoxO3a (Thr32), 
Phospho-GSK-3β (Ser9), Phospho-IRS-1 (S636/639), MEF2A, mTOR, PKCα, S6 Ribosomal 
Protein, Phospho-S6 Ribosomal Protein (Ser235/236) and p70 S6 kinase from Cell 
Signaling. Rabbit monoclonal antibodies: β-actin, Phospho-Akt (Ser473), Cox IV, FoxO3a 
(75D8), GSK-3β, IRS-1, PI3 Kinase p85, Raptor and Rictor from Cell Signaling and PPARγ 
from Santa Cruz. Mouse monoclonal antibodies: α-actinin and myosin (skeletal, slow) from 
sigma, β-tubulin and Mef2D from BD Biosciences. Goat polyclonal antibody: GP from Santa 
Cruz. 
 
Tissue homogenization, immunoprecipitation, SDS PAGE and Western blot 
Muscles frozen in liquid nitrogen were powdered on dry ice, transferred to cold RIPA buffer 
supplemented with 1% Triton-X, 10% glycerol, protease inhibitor cocktail tablets (Roche) and 
phosphatase inhibitor cocktail I and II (Sigma). Cell lysates were incubated on ice for 2 
hours, sonicated 2 times for 15 seconds and centrifuged at 13,600g for 30 min at 4°C. 
Cleared lysates were then used to determine total protein levels (BCA Protein Assay, 
Pierce). After dilution with sample buffer, equal protein amounts were loaded onto SDS gels. 
 
Histology and immunohistochemistry 
Muscles frozen in liquid nitrogen-cooled isopentane were fixed with 2% PFA and cut into 12 
µm cross-sections. Cross-sections were permeabilized with 1% Triton/PBS for 5 min, 
washed with 100 mM glycine/PBS for 15 min, blocked with 1% BSA/PBS for 30 min and 
incubated with specific primary antibody overnight at 4oC. Samples were subsequently 
washed with 1% BSA/PBS, 3 times for 1 hour, stained with appropriate fluorescently labeled 
secondary antibodies for 1 hour at room temperature. After washing with PBS, samples were 
mounted with Citifluor (Citifluor Ltd). General histology on cross-sections was performed 
using hematoxylin and eosin (H&E; Merck, Rayway, NJ, USA). NADH staining was done as 
described [157]. Periodic acid-schiff staining (PAS staining system, Sigma) was performed 
according to the manufacturer's instruction. After H&E, NADH and PAS staining, samples 
were dehydrated and mounted with DePeX mounting medium (Gurr, BDH). 
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3.2.7. Figures and tables 
 
 
 
 
Figure 1. Targeting strategy and initial characterization of RAmKO and RImKO mice 
(A) Schematic presentation of wild-type and targeted alleles of raptor (left panel) and rictor (right 
panel) before and after recombination. Localization and size of DNA fragments generated by particular 
restriction digests are indicated. Probes used for Southern blot analysis are shown by hatched bars. 
PCR primers for genotyping are indicated by arrows. +: wild-type allele; fl-neo: targeted allele; fl: 
alleles after recombination by FRT; -: alleles after recombination by Cre. (B) Southern blot analysis of 
genomic DNA from ES cells and F1 progeny of resulting chimeras. Correct targeting of the 5’ end is 
indicated by the presence of a 6.0 kb band in the raptor locus and a 7.3 kb band in the rictor locus. 
Correct targeting at the 3’ end is indicated by a 6.1 kb and a 7.3 kb band, respectively. In each blot of 
ES cells, wild-type is to the left. (C) Western blot analysis of protein extracts from skeletal muscle of 
RAmKO and RImKO mice. Controls correspond to muscle extracts from mice that carry the floxed 
alleles but are negative for HSA-Cre. Equal protein loading is confirmed by blotting for α-actinin. 
(D) Growth curve of RAmKO, RImKO and control mice. Mice of each genotype were weighed every 
week. A significant difference between RAmKO and control mice (p<0.05) was observed after the age 
of 63 days. Individual data points represent means ± SEM (N = 5 for RAmKO; N = 3 for RImKO; N = 
10 for controls). (E) Photograph of 140 day-old RAmKO, control (ctrl) and RImKO mice. (F) Survival 
curve of RAmKO , RImKO and control mice. 
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Figure 2. Muscle of RAmKO mice show signs of a progressive dystrophy 
(A) Hematoxylin & Eosin (H&E) staining of muscle cross-sections from the EDL and soleus (Sol) 
muscle of 140 day-old mice. In EDL muscle of RAmKO mice, some large (blue arrowheads) but also 
small fibers are present. Centralized nuclei (white arrowheads) and central core-like structures (black 
arrowheads) can be found in soleus muscle of RAmKO mice. Both muscles contain many 
mononuclear cells (green arrowheads). (B) Longitudinal section of soleus muscle of a 140 day-old 
RAmKO mouse. Besides centrally aligned nuclei (white arrowheads), central core-like structures 
(black arrowheads), which expand longitudinally in muscle fibers are visible. (C, D, E, F) Fiber size 
distribution in the soleus muscle of 90 day- (C) and 140 day-old (D), and in the EDL muscle of 90 day- 
(E) and 140 day-old (F) RAmKO and control mice. (G) Mean percentage of muscle fibers with 
centralized nuclei (cnf) in the soleus and EDL muscle of RAmKO and control mice. (H) Percentage of 
muscle fibers containing central core-like structures (ccls) in soleus and EDL muscle of RAmKO and 
control mice. (I) H&E staining of cross-sections of the diaphragm of 90 day- and 140 day-old RAmKO 
and control mice. Individual data points and bars (C – H) represent mean ± SEM (N=4 mice). Scale 
bars (A, B, I) = 50 µm. P-values are: *** p< 0.001; ** p< 0.01; * p< 0.05. 
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Figure 3. Metabolic and structural properties diverge in skeletal muscle of RAmKO mice 
(A) Preparation of the entire hindleg isolated from 90 day-old mice of the genotypes indicated. Note 
that soleus muscle (arrowheads) is pale in RAmKO mice compared to RImKO and control mice. 
(B) Activity of oxidative enzymes examined by NADH-tetrazolium staining (blue precipitate) in EDL 
and soleus muscle of 140 day-old mice. Central core-like structures devoid of NADH staining (black 
arrowheads) and increased subsarcolemmal reactivity (red arrowheads) was detected in some 
RAmKO soleus fibers. (C) Electron micrographs of longitudinal sections of soleus muscle from 140 
day-old mice. Most intermyofibrillar mitochondria in RAmKO muscle are lost from their specific position 
next to Z disks (red arrows, upper panel). Remaining mitochondria in RAmKO mice show high 
morphologic variability (red arrow, lower panel). (D) Periodic acid-schiff (PAS) staining of cross-
sections from 140 day-old mice. The reaction product (magenta color) is indicative of the amount of 
glycogen in the tissue. (E) Glucose tolerance test with 65 day-old mice (N=8 for RAmKO and N=11 for 
control mice). (F) Immunostaining for slow myosin heavy chain (slMHC; green) and the laminin γ1 
chain (red) of cross-section from 140 day-old mice. (G & H) Quantification of slMHC-positive muscle 
fibers in soleus and EDL muscle from 90- and 140 day-old mice (N = 4). (I) Western blot analysis for 
slMHC and slow troponin T (slTnT) using soleus muscle of 90 day-old mice. α-actinin is shown as a 
  53
loading control. (J) Relative mRNA levels of the slow skeletal muscle troponin I isoform (slTnI) in the 
soleus of 90 day-old mice as determined by QRT-PCR (N = 3). Individual data points and bars (E, G, 
H, J) represent mean ± SEM. Scale bars = 50 μm (B, D), 2 μm (upper pictures C), 250 nm (lower 
pictures C) and 125 µm (F). P-values are: *** p< 0.001; ** p< 0.01; * p< 0.05. 
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Figure 4. Exercise performance and muscle physiology  
(A) Representative, activity chart with bins of 10 seconds from a single 95 day-old RAmKO or a control 
mouse. Charts were measured from 6 pm to 6 am (dark cycle). (B) Average distance run per day 
determined during one week (starting at the age of 90 days, N = 4 for RAmKO and N = 9 for controls). 
(C) Average of the top 10% speed measured over one week (starting at the age of 90 days, N = 4 for 
RAmKO and N = 9 for controls). (D) Grip strength of 90 day-old RAmKO and control mice. Average 
time mice were able to hold on a horizontal grid was normalized to body weight. Values of control mice 
were set to 100% (N = 3). (E) Force capacity resistance of EDL or soleus muscle isolated from 140 
day-old mice was measured during muscle fatigue induced by intermittent tetanic stimulation. Trains of 
150 Hz tetani of 350 ms duration were given at 3.6 s intervals. (N = 3 for RAmKO and N = 4 for control 
mice). Individual data points and bars (B – E) represent mean ± SEM. P-values are: *** p< 0.001; ** 
p< 0.01; * p< 0.05. 
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Figure 5. Biochemical characterization 
(A,B,D,F) Western blot analysis of soleus muscle from 90 day-old RAmKO, RImKO and control mice 
using antibodies directed against the proteins indicated (for details see Experimental Procedures). 
Equal amount of protein was loaded in each lane. Antibodies to α-actinin and PI3K were in addition 
used as loading controls. (C & E) Relative mRNA levels of MuRF1, MAFbx, myoglobin (myogl.) and 
PGC1α in soleus muscle of 90 day-old RAmKO or control mice. Values obtained in controls were set 
to 100% (N = 3). (G & I) Western blot analysis of soleus muscle from 60 day-old DmKO and control 
mice. (H) PAS and NADH-TR staining on cross-sections of triceps muscles from 50 day-old DmKO 
and control mice. (J) Immunostaining with antibodies specific for P-PKB/AktS473 using cross-sections of 
60 day-old DmKO and control mice. (K) Schematic of the interactions contributing to the phenotype of 
RAmKO mice. Signaling pathway downstream of the insulin/IGF receptor is shown. Blue arrows with 
open arrowheads represent interactions that affect gene transcription; black symbols represent 
regulation on the protein level that activate or inhibit the targets. Abbreviations are: atg: atrogenes 
(MuRF1 and MAFbx), GP: glycogen phosphorylase; GS: glycogen synthase; IGF-R: IGF receptor; Mb: 
myoglobin; slSP: slow structural proteins. Data (C, E) represent mean ± SEM. Scale bars (H, J): 50 
μm. P-values are: ** p< 0.01; * p< 0.05. 
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Table 1 90d  140d 
 ctrl RAmKO  ctrl RAmKO 
Tibia length (cm) 2.0 ± 0.1 2.0 ± 0.1  2.0 ± 0.1 2.1 ± 0.1 
Lower hindleg (mg) 449.2 ± 19.3 344.0 ± 11.4***  428.0 ± 28.0 331.6 ± 41.3** 
Triceps brachii (mg) 98.3 ± 11.3 67.0 ± 10.4***  89.5 ± 14.0 68.8 ± 13.8* 
Soleus (mg) 9.7 ± 0.8 7.4 ± 0.6***  9.2 ± 0.8 7.1 ± 1.2* 
EDL (mg) 12.7 ± 0.8 10.3 ± 0.7***  12.0 ± 0.7 9.4 ± 1.4* 
Tibialis anterior (mg) 58.3 ± 2.7 40.8 ± 2.3***  55.6 ± 1.8 39.0 ± 1.3*** 
Epididymal fat pad (mg) 566.4 ± 214.9 438.9 ± 93.1  616.0 ± 194.8 242.5 ± 118.7** 
Heart (mg) 85.12 ± 6.6 68.1 ± 4.1*  88.5 ± 2.1 72.1 ± 4.4** 
Liver (mg) 1350.9 ± 185.0 1187.5 ± 161.0  1232.0 ± 187.5 1055.0 ± 269.1 
* p<0.05, ** p<0.01, ***p<0.001      
 
Table 1. Analysis of particular tissues in control and RAmKO mice. Weight or length was 
measured for different muscles, bones and other organs in 90- and 140 day-old mice. P-values 
determined by Student's t-test are indicated by asterisks (N = 4 mice). Values represent mean ± SD. 
 
 
Table 2 EDL  Sol 
 ctrl RAmKO  ctrl RAmKO 
Twitch      
Time to peak (ms) 10.1 ± 0.9 11.1 ± 1.2  20.3 ± 4.2 39.7 ± 2.4*** 
Half time to peak (ms) 3.0 ± 0.4 3.5 ± 0.5  5.6 ± 0.6 11.6 ± 1.1*** 
Half relaxation time (ms) 15.5 ± 2.2 16.8 ± 3.3  30.8 ± 8.7 63.0 ± 5.1*** 
Absolute force (mN) 54.0 ± 13.2 45.0 ± 9.7  30.0 ± 5.6 21.0 ± 8.1* 
Tetanus      
Half contraction time (ms) 16.6 ± 2.0 14.4 ± 1.1*  27.5 ± 5.4 41.0 ± 5.4*** 
Half relaxation time (ms) 22.1 ± 1.3 24.1 ± 1.6*  55.2 ± 3.9 124.4 ± 13.2*** 
Absolute force (mN) 311 ± 57.6 224 ± 38.1**  205 ± 20.8 164.0 ± 42.83 
Specific force (mN/mm2) 380.2 ± 57.2 328.3 ± 62.7  311.6 ± 56.3 264 ± 66.9 
* p<0.05, ** p<0.01, ***p<0.001 
 
Table 2. Analysis of the contractile properties of EDL and soleus muscles of control and 
RAmKO mice. Data were recorded from EDL and soleus muscles of 140 day-old mice. P-values 
determined by Student's t-test are indicated by asterisks (N = 3 for RAmKO and N = 4 for control 
mice). Values represent mean ± SD. 
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3.2.8. Supplemental data 
 
Supplemental experimental procedures 
Mice 
PAC clones from the RPCI-21 (129S6) mouse genomic DNA library [158] were identified by 
hybridization with cDNA encoding the targeted exons. For raptor, a 6.9 kb SmaI fragment 
spanning 2.9 kb upstream and 3.8 kb downstream of raptor exon 6 was isolated from clone 
RPCI-21 388E14 and cloned into pBluescript (Stratagene). For the rictor targeting construct, 
a 10.3 kb EcoRI fragment that encompassed 4.5 kb upstream of exon 4 and 4.5 kb 
downstream of exon 5 was isolated from clone RPCI-21 520C16 and ligated into pBluescript. 
Using homologous recombination (ET cloning) as well as Cre-driven recombination in 
bacteria and standard cloning procedures, recombination sites, a selection cassette and 
diagnostic restriction sites were added to the vectors. The neomycin resistance (PGK-TK-
neo) cassette flanked by two Frt recombination sites and a 5’-LoxP site was added 283 bp 
upstream of exon 6 in the raptor construct and 304 bp upstream of exon 4 in the rictor 
construct [159]. The 3’-LoxP sites were located 277 bp downstream of raptor exon 6 and 301 
bp downstream of rictor exon 5, respectively. The targeting vectors were linearized and 
electroporated into R1 ES cells derived from 129S6 mice [160]. Clones were analyzed for 
correct integration by Southern blot analysis using both 5’- and 3’-probes (see Figures 1A 
and B). Chimeric mice were obtained by microinjection of the correctly targeted clones into 
C57BL/6 blastocysts. Chimeric mice were crossed with C57BL/6 mice to obtain germline 
transmission. Mice analyzed in this study were backcrossed to C57BL/6 for 4 generations. 
The backcrosses involved mice constitutively expressing the FLP recombinase to excise the 
neomycin cassette from the targeted allele [125] and mice expressing the Cre recombinase 
under the human skeletal actin promoter [87]. As indicated in Figure 1, PCR genotyping of 
RAmKO mice was performed with primers P1: 5' ATG GTA GCA GGC ACA CTC TTC ATG 
and P2: 5' GCT AAA CAT TCA GTC CCT AAT C, resulting in an amplicon of 228 bp in case 
of presence of the FRT site and of 141 bp in case of the wild-type allele. For RImKO mice, 
primers P1: 5' TTA TTA ACT GTG TGT GGG TTG and P2: 5' CGT CTT AGT GTT GCT GTC 
TAG, resulting in an amplicon of 295 bp in case of presence of the FRT site and of 197 bp in 
case of a wild-type allele were used. The monoallelic presence of the Cre recombinase was 
detected using primers F: 5' TGT GGC TGA TGA TCC GAA TA and B: 5' GCT TGC ATG 
ATC TCC GGT AT resulting in an amplicon of 249 bp. Tissue-specific LoxP recombination in 
RAmKO mice was determined with primers P1 and P3: 5' CTC AGA GAA CTG CAG TGC 
TGA AGG, resulting in an amplicon of 204 bp for the recombined allele and no product for 
the wild-type or unrecombined allele (Figure 1C). LoxP recombination in RImKO mice was 
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detected using primers P1 and P3: 5' CAG ATT CAA GCA TGT CCT AAG C resulting in a 
PCR product of 280 bp in presence of the recombined allele and in no product in wild-type or 
unrecombined allele. DmKO mice were genotyped with the primers used for RAmKO and 
RImKO mice. Brain-specific raptor and rictor knockout mice were obtained by crossing floxed 
mice with Nestin-Cre mice [86]. Mdx mice were obtained from the Jackson Laboratory. 
 
Animal care, body weight, food intake and body temperature measurements 
Mice were maintained in a conventional facility with a fixed light cycle. Studies were carried 
out according to criteria outlined for the care and use of laboratory animals and with approval 
of the Swiss authorities. Body weight, food intake and body temperature were measured 
weekly. A medical precision thermometer DM 852 from Ellab was used for the body 
temperature measurements. 
 
Real-time PCR 
Total RNA was isolated (SV Total RNA isolation System, Promega) from soleus muscles. 
Reverse transcription was carried out using a mixture of oligodT and random hexamer 
primers (iScript cDNA Synthesis Kit, Bio-Rad). Sybr Green, real-time PCR analysis (Power 
SYBR Green Master Mix, Applied Biosystems) was performed using the ABI Prism 7000 
Sequence Detector. Expression levels for each gene of interest were normalized to the mean 
cycle number using real-time PCR for the two housekeeping genes β-actin and Polr2A. In all 
experiments, the ratio between β-actin and Polr2A was constant. The following primers were 
used: β-actin sense primer: 5' CAG CTT CTT TGC AGC TCC TT, antisense primer: 5' GCA 
GCG ATA TCG TCA TCC A; Polr2A sense primer: 5' AAT CCG CAT CAT GAA CAG TG, 
antisense primer: 5' CAG CAT GTT GGA CTC AAT GC; MAFbx sense primer: 5′ CTC TGT 
ACC ATG CCG TTC CT, antisense primer: 5′ GGC TGC TGA ACA GAT TCT CC; MuRF1 
sense primer: 5′ ACG AGA AGA AGA GCG AGC TG, antisense primer: 5′ CTT GGC ACT 
TGA GAG GAA GG; slTnI sense primer: 5’ GTG CCT GGA ACA TCC CTA AT, antisense 
primer: 5’ TGA GAG GCT GTT CTC TCT GC; PGC1α sense primer: 5' AAC GAT GAC CCT 
CCT CAC AC, antisense primer: 5' TCT GGG GTC AGA GGA AGA GA; myoglobin sense 
primer: 5' ATC CAG CCT CTA GCC CAA TC, antisense primer: 5' GAG CAT CTG CTC CAA 
AGT CC. 
 
In vitro muscle strength assessment 
EDL and soleus muscles were dissected and mounted into a muscle testing setup 
(Heidelberg Scientific Instruments). Muscle force assessment was carried out as previously 
described [161].  
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Voluntary wheel running 
Animals were individually housed in cages equipped with a running wheel carrying a magnet. 
Wheel revolutions were registered by a reed sensor connected to an I-7053D Digital-Input 
module (Spectra), and the revolution counters were read by a standard laptop computer via 
an I-7520 RS-485-to-RS-232 interface converter (Spectra). Digitalized signals were 
processed by the "mouse running" software developed by Santhera Pharmaceuticals. 
 
Assessment of muscle fiber membrane damage 
Mice were forced to run downhill on a treadmill with an inclination of 15°, at the speed of 10 
m/min for 10 min. This procedure was repeated for 3 days. After the second running session, 
Evans blue dye (1 mg / 0.1 ml PBS / 10 g body weight) was injected intraperitoneally. Mice 
were sacrificed 1 hour after the last running session and cross-sections of the entire hindleg 
were analyzed [162]. 
 
Glucose tolerance test 
60 to 65 day-old mice were fasted overnight, followed by an intraperitoneal injection of 2 g/kg 
glucose. Blood was obtained from the tail vein at the indicated time points and analyzed 
using a OneTouch UltraMini Meter (Lifescan). 
 
Electron microscopy 
Transmission electron microscopy was performed as described [163].  
 
Tissue culture  
C2C12 cells were differentiated using DMEM containing 5% horse serum for 72 h before 
treatments with vehicle or rapamycin (8 or 16 h at 20 nM). 
 
Heart weight and function 
Under isoflurane anaesthesia, parasternal short axis M- and B-mode images of the left 
ventricle were obtained using a VisualSonics 770 machine with a 40-MHz linear transducer. 
Heart rate (HR), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic 
diameter (LVESD), diastolic and systolic posterior wall and septum thickness were 
determined. Fractional shortening (%FS) was calculated as (LVEDD-LVESD)/EDD x 100. 
Left ventricular weight was calculated from the cardiac dimensions obtained by the 
VisualSonics system and confirmed by directly weighing the wet hearts after sacrification of 
the mice. 
 
 
  61
Quantifications and statistics 
Muscle glycogen concentration was measured in homogenates after 2 h of hydrolysis in 2N 
HCl at 100°C. The resulting free glucosyl units were determined using a commercial 
hexokinase-based assay kit (Sigma). For muscle fiber size quantification, pictures were 
collected using a Leica DM5000B fluorescence microscope, a digital camera (F-View; Soft 
Imaging), and analySIS software (Soft Imaging System). Muscle fiber size distribution was 
determined on laminin-γ1 immunostained muscle cross-sections using the minimum distance 
of parallel tangents at opposing particle borders (minimal "Feret’s diameter") as described 
elsewhere [164]. Quantification of Western blots was performed using the ImageJ software. 
Background-corrected grey values were normalized to total protein levels. Compiled data are 
expressed as mean ± SEM. For statistical comparisons of two conditions, the Student’s t- 
test was used. The level of significance is indicated as follows: *** p< 0.001, ** p< 0.01, * p< 
0.05. 
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 Supplementary table S1 
 
 RAmKO ctrl ratio number of replicates RImKO ctrl ratio 
number of 
replicates DmKO ctrl ratio 
number of 
replicates 
Raptor 11 ±3* 61 ±11 0.2 3 42 ±1* 51 ±2 0.8 3 2 ±0.5* 35 ±11 0.06 3 
mTOR 4 ±2 11 ±4 0.4 4 24 ±5 26 ±1 0.9 3 2 ±1* 17 ±5 0.1 3 
Rictor 9 ±1 8 ±1 1.2 4 26 ±1* 59 ±7 0.4 3 17 ±4* 38 ±7 0.4 4 
S6K 56 ±5** 27 ±3 2.1 3 24 ±4 90 ±1 0.3 3     
S6 82 ±35 114 ±12 0.7 3 35 ±5 29 ±6 1.2 3 7 ±3 14 ±6 0.5 3 
P-S6S235/S236 3 ±1* 21 ±5 0.1 6 19 ±8 57 ±24 0.3 4 21 ±8 44 ±16 0.5 3 
4E-BP1 28 ±5 38 ±5 0.7 4 32 ±5 28 ±7 1.1 4     
P-4E-BP1S65 4 ±2* 16 ±2 0. 3 4 49 ±12 41 ±10 1.2 4     
PKB/ Akt  104 ±4 129 ±11 0.8 3 14 ±1 27 ±7 0.5 3 12 ±4 15 ±5 0.8 3 
P-PKB/ AktT308 9 ±3* 1 ±0.3 8 4 41 ±1* 55 ±3 0.7 3 24 ±6* 0.6 ±3 40 3 
P-PKB/ AktS473 9 ±1.5** 1 ±0.5 9.6 4 37 ±6** 98 ±11 0.4 3 22 ±5* 10 ±3 2.3 4 
PKCα 31 ±5 25 ±3 1.2 5 11 ±3*** 49 ±6 0.2 4 17 ±5 24 ±7 0.7 3 
P-PKCαS657 26 ±9 40 ±7 0.6 6 6 ±1** 58 ±11 0.1 3 48 ±17 35 ±10 1.4 3 
FoxO1 61 ±4*** 20 ±3 3.1 3 27 ±3 17 ±8 1.6 3       
P-FoxO1S316 29 ±10 37 ±7 0.8 5 62 ±5 62 ±11 1 3       
FoyO3a 70 ±6*** 22 ±3 3.3 4 34 ±3 38 ±6 0.9 4       
P-FoyO1T24/3a/T23 35 27 
±7*/ 
±4 
8
28
±2/ 
±1 
4.5/ 
1 4 
30
31
±2/ 
±4 
33
29
±6/ 
±7 
0.9/ 
1.1 4       
IRS-1 74 ±6*** 11 ±1 6.7 3             
P-IRS-1S636/639 41 ±14** 3 ±1 13.7 4             
Erk1/2 104 59 
±10 / 
±13 
86
29
±3/ 
±4 
1.2/ 
2 3             
P-Erk1/2T185/Y187 3 16 
±1.5 / 
±2 
2
18
±0.5/ 
±4 
2/ 
0.9 3             
GSK3β 80 ±4 69 ±4 1.2 3             
P-GSK3βS9 39 ±13* 8 ±1 4.9 3             
Glycogen phos. 15 ±7* 51 ±7 0.3 3             
Calcineurin 31 ±4 21 ±2 1.5 4             
Mef2A 126 ±12* 64 ±11 2 3             
Mef2D 36 ±3 30 ±5 1.2 4             
PPARγ 19 ±3** 41 ±3 0.5 3             
COX IV 10 ±2** 20 ±2 0.5 6             
slMHC 42 ±0.5** 15 ±6 2.7 4         
slTnT 73 ±4*** 36 ±2 2.0 4           
* p<0.05, ** p<0.01, ***p<0.001 
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Supplementary table S1. Quantification of Western blot analysis for the proteins indicated. Proteins analyzed were extracted from soleus muscle of 90 day-old 
RAmKO, RImKO or control (ctrl) littermates. For the analysis of the DmKO mice, 60 day-old mice were compared with control littermates. Amount of total protein 
loaded onto the SDS-PAGE was adjusted and Western blots were additionally normalized with antibodies to α-actinin. Numbers given represent average grey 
values ± SEM after subtraction of the background. "Ratio" represents the average grey value obtained from a knockout animal divided by the grey values from 
the control littermates. "Number of replicates" represents the number of knockout animals analyzed. The number of control littermates was always the same or 
higher than the values given. P-values were determined by student’s t-test. 
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Supplemental figures 
 
Figure S1. Specificity of recombination and characterization of RAmKO mice. (A) PCR on 
40 ng of genomic DNA extracted from tibialis muscle (Tib.) or the heart (Hrt.) of 60 day-old 
RAmKO, RImKO or control (ctrl) littermates. The PCR product indicating successful 
recombination by Cre recombinase (primers P1 and P3, see Fig. 1A for details) is only observed 
in tibialis muscle and not in the heart of RAmKO or RImKO mice. Note that as a result of 
recombination, less PCR product than in control mice was detected of the non-recombined locus 
(P1-P2 primers). (B) Western blot analysis of EDL muscle from 90 day-old RImKO and control 
mice and with brain lysates isolated from mice homozygously carrying either the floxed rictor or 
raptor alleles and expressing the Cre recombinase under control of the nestin promonter (Nestin-
Cre). α-actinin, β-actin and β-tubulin were used as loading controls. (C) Average daily food intake 
of RAmKO and control (ctrl) mice between the age of 42 to 140 days (N = 5 for RAmKO; N = 8 for 
controls). (D) Dorsal view on a 140 day-old skinned, male RAmKO or control mouse. Hindleg 
muscles of the RAmKO mouse appear thinner and no fat pads (asterisk in ctrl mouse) can be 
detected. (E) Basal body temperature measured at the age of 90 and 140 days does not differ 
between RAmKO and control mice (N=4). (F) Left ventricular mass divided by the total body 
weight (LV/BW) does not change between 140 day-old control and RAmKO mice (N = 3 mice). 
Bars represent mean ± SEM. 
  65
 
 
 
 
Figure S2. Expression pattern and assessment of muscular dystrophy parameters in 
RAmKO mice. (A) Expression of selected proteins of the PKB/Akt and mTOR pathway in soleus 
and EDL muscle of wild-type C57/BL6 mice. Amount of total protein loaded was adjusted and 
additionally normalized to the levels of α-actinin. For quantification, grey values relative to α-
actinin were measured for each protein and set to 100% for soleus (N = 3 mice). (B) 
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Immunohistochemistry for tenascin-c and f4/80 (green) and DAPI staining (blue) reveals 
increased formation of fibrotic tissue and the presence of inflammatory monocytes (white 
arrowheads) in the soleus muscle of 140 day-old RAmKO mice. (C) Evans blue dye (EBD) 
incorporation in the lower hindleg of 90 day-old RAmKO and control (ctrl) mice after 3 days of 
forced treadmill running. No EBD positive fibers could be found in control or RAmKO muscles. In 
mdx mice, which served as an experimental control, massive incorporation of EBD was observed. 
(D) The number of fibers in the soleus of 180 day-old RAmKO mice is the same as in control 
littermates (N=4). (E) Maximal intensity projection using confocal microscopy of a whole mount 
preparation of neuromuscular junctions of the diaphragm of a 90 day-old control (ctrl) or RAmKO 
mouse. Acetylcholine receptors (AChRs) were visualized by TRITC-conjugated α-bungarotoxin. 
There is no difference between the two genoytypes. (F) Low magnification pictures of diaphragms 
of 90 day-old mice stained with TRITC-α-bungarotoxin. The innervation band can be discerned at 
the bottom of each picture. Extrasynaptic AChR clusters (white arrowheads) are found in the 
diaphragm of RAmKO mice. Bars represent mean ± SEM. Scale bars = 50 μm (B & C), 10 μm 
(D), 100 μm (E). P-value: * p< 0.05. 
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Figure S3. Fiber size distribution and cytoskeletal architecture in RImKO mice. 
(A) Fiber size distribution in soleus muscle of 90 day-old RImKO and control mice. There is no 
difference between the two genotypes. Data points represent mean ± SEM (N = 3 mice). (B) 
Maximal intensity projection using confocal microscopy of muscle fibers from 90 day-old mice 
stained with antibodies to α-actinin. No difference in the sarcomeric organization was observed. 
Scale bar = 20 μm. 
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Figure S4. Subsarcolemmal accumulation of misshaped mitochondria and regionalized 
slMHC expression in RAmKO mice. (A) Representative high power electron micrographs of 
RAmKO and control (ctrl) soleus muscle. Subsarcolemmal mitochondria in RAmKO mice are 
morphologically abnormal (asterisk marks a single mitochondrion) and mitochondria are more 
densely packed than in control mice. (B) Immunostaining for slMHC (green) using cross-sections 
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of the entire hindleg of RAmKO and control mice. Individual muscles are outlined by red, dotted 
lines. A: soleus; B: plantaris-adjacent gastrocnemius; C: gastrocnemius; D: peroneus longus and 
peroneus brevis; E: extensor digitorum longus (EDL); F: tibialis anterior. Note that the expression 
of slMHC in RAmKO mice is high in particular regions of muscles. Scale bars = 1 µm (A), 200 μm 
(B). 
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Figure S5. In-vivo and in-vitro alterations of Ser473-phosphorylated PKB/Akt, Mef2A and 
slMHC. (A) Cross-sections of the hindleg isolated from 90 day-old RAmKO or control (ctrl) mice 
were stained with antibodies directed against PKB/Akt phosphorylated on Ser473 (P-
PKB/AktS473). Soleus muscle (asterisk) shows particularly high levels of P-PKB/AktS473 along the 
sarcolemmal membrane in RAmKO mice. Scale bar = 125 μm. (B) Western blot analysis of EDL 
muscle from 90 day-old RAmKO and control (ctrl) mice using antibodies to Mef2A. Amount of 
total protein loaded was adjusted and SDS gels were stained with colloidal blue (bottom) as a 
loading control. Levels of Mef2A are increased in RAmKO compared to control mice. (C) Western 
blot analysis of C2C12 cells that were treated for either 8 or 16 hours with rapamycin. β-tubulin 
was used as a loading control. As determined by quantification of grey-values (N=3), treatment of 
C2C12 cells with rapamycin for eight or sixteen hours caused a significant loss of S6 
phosphorylation. A slight, non-significant increase in P-PKB/AktS473 was observed after 16 hour 
treatment. None of the other proteins was changed.  
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4. Concluding remarks 
 
In this study, we knocked out the gene of the essential mTORC1 component raptor 
specifically in muscle fiber and in the developing CNS. In both mouse models, growth 
defects contributed substantially to the phenotype. Whereas in the brain, mTORC1 is 
necessary during prenatal brain growth, body weight of muscle-specific ko mice is 
normal at birth. A progressive dystrophy of skeletal muscle and loss of fat causes weight 
loss which increases with age.  
 
In the newborn brain-specific ko mice, brain size is massively decreased to 55%. The 
whole brain is evenly affected. Smaller cells and a slower proliferation rate are 
responsible for this growth deficit. Several more specific phenotypes are superimposed 
to this pronounced microcephaly. Stat3 was previously described as a direct 
downstream target of mTORC1. In the CNS, Stat3 is involved in the neurogenic to 
gliogenic switch and drives glial differentiation. A positive feedback mechanism allows 
activated (phosphorylated) Stat3 to induce expression of itself and other members of the 
Jak/Stat pathway. In the raptor-deficient brain, phosphorylation- and protein-levels are 
indeed reduced. In line with this observation, gliogenesis is reduced in mutant brains. 
The glial network of the dentate gyrus which mediates proper formation of the granule 
cell layer is largely absent and neurons in the dentate gyrus are dispersed throughout 
the hylus. In the cortical plate, the signal for the dendritic marker Map2 is decreased and 
dendritic complexity is reduced in dissociated hippocampal cultures. Further, this study 
shows that mTORC1 is crucial for normal migration of neurons in the prenatal cortex and 
hippocampus. 
 
Progressive loss of muscle mass may be accounted for by a decreased mTORC1 
dependent protein synthesis. mTORC1-independent anabolic functions of hyper-
activated Akt/PKB also contributed to the overall phenotype. This combination from 
catabolic effects resulting from 4EBP1-, S6K/S6- and PGC1α-inactivation and anabolic 
effects from active Akt/PKB may explain some of the seemingly conflicting results. 
Defects in mitochondrial biogenesis and concurrent reductions in oxidative capacity of 
the muscle is caused by downregulation of the mTORC1-downstream component 
PGC1α. A direct or indirect activation of Mef2 by Akt/PKB, however, may account for the 
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expression of slow structural proteins. Additionally to the reduced oxidative capacity, 
hyperactive Akt/PKB may cause the high glucose need of raptor-deficient muscles by 
disinhibition of the glycogen synthase causing glycogen accumulation. This may 
ultimately also explain the observed loss of fat. 
 
Both models reveal novel and partially unexpected physiological functions of mTORC1 
in the respective tissues. Ablation of mTORC1 in both tissues shortens life, most 
dramatically when deleted in the brain. Partially via regulation of its direct downstream-
effectors, mTORC1 is essential for growth and the correct cellular composition as well as 
organization of muscle and brain. 
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